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ABSTRACT 
Neuropeptides are the largest group of signalling chemicals that can convey the 
information from the brain to the cells of all tissues. DPKQDFMRFamide, a member of 
one of the largest families of neuropeptides, FMRFamide-like peptides, has modulatory 
effects on nerve-evoked contractions of Drosophila body wall muscles (Hewes et aI., 
1998) which are at least in part mediated by the ability of the peptide to enhance 
neurotransmitter release from the presynaptic terminal (Hewes et aI., 1998, Dunn & 
Mercier., 2005). However, DPKQDFMRFamide is also able to act directly on Drosophila 
body wall muscles by inducing contractions which require the influx of extracellular Ca 2+ 
(Clark et aI., 2008). The present study was aimed at identifying which proteins, including 
the membrane-bound receptor and second messenger molecules, are involved in 
mechanisms mediating this myotropic effect of the peptide. DPKQDFMRFamide-
induced contractions were reduced by 70% and 90%, respectively, in larvae in which 
FMRFamide G-protein coupled receptor gene (CG2114) was silenced either ubiquitously 
or specifically in muscle tissue, when compared to the response of the control larvae in 
which the expression of the same gene was not manipulated. Using an enzyme 
immunoassay (EIA) method, it was determined that at concentrations of 1 ~M- 0.01 ~M, 
the peptide failed to increase cAMP and cGMP levels in Drosophila body wall muscles. 
In addition, the physiological effect of DPKQDFMRFamide at a threshold dose was not 
potentiated by 3-lsobutyl-1-methylxanthine, a phosphodiesterase inhibitor, nor was the 
response to 1 ~M peptide blocked or reduced by inhibitors of cAMP-dependent or 
cGMP-dependent protein kinases. The response to DPKQDFMRFamide was not affected 
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in the mutants ofthe phosholipase C-~ (PLC~) gene (norpA larvae) or IP3 receptor 
mutants, which suggested that the PLC-IP3 pathway is not involved in mediating the 
peptide's effects. Ala1 transgenic flies lacking activity of calcium/calmodulin-dependent 
protein kinase (CamKII) showed an increase in muscle tonus following the application of 
1 JlM DPKQDFMRFamide similar to the control larvae. Heat shock treatment 
potentiated the response to DPKQDFMRFamide in both ala1 and control flies by 
approximately 150 and 100 % from a non heat-shocked larvae, respectively. 
Furthermore, a CaMKII inhibitor, KN-93, did not affect the ability of peptide to increase 
muscle tonus. Thus, although DPKQDFMRFamide acts through a G-protein coupled 
FMRFamide receptor, it does not appear to act via cAMP, cGMP, IP3, PLC or CaMKl1. The 
mechanism through which the FMRFamide receptor acts remains to be determined. 
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1. INTRODUCTION AND LITERATURE REVIEW 
1.1 Brief outline of the matter 
The survival of an organism depends on its ability to monitor its external 
environment and to adapt its behaviour in response to changes in the environment. This 
is evident even in the life of simple unicellular eukaryotes such as Dictyostelium 
discoideum, a slime mould. When exposed to starvation, cells of D. discoideum secrete a 
chemoattractant, cAMP, that acts on neighbouring cells, presumably directly through 
cAMP receptors (Devrotes, 1983; Henderson, 1975). When neighbouring cells detect 
extracellular cAMP they move toward the source. At the same time, intracellular cAMP 
levels in cells that received the signal increase, which is followed by the secretion of 
more cAMP into the extracellular environment and, consequently, the chemoattracting 
signal propagates to other cells. As a result, several thousand cells are able to aggregate 
forming a multicellular fruiting body (Gerish, 1982; Deverotes, 1983). Although chemical 
signalling in multicellular organisms has evolved strikingly from that in unicellular 
organisms, it is still similar in the way that the response to external cues is a result of the 
ability of individual cells, specialized to carry out a specific physiological function, to_ 
coordinate their activities. Hence, unicellular and multicellular organisms developed 
systems by which cells can communicate with each other to produce integrated 
physiological and behavioural responses. 
A major class of chemical signals, neuropeptides, are chemical signals that convey 
the information from one nerve cell to another nerve cell, or to a cell of a distant non-
neuronal tissue. This allows for the regulation of various developmental and 
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physiological processes and processes involved in generating animal behaviour. Hence, 
the disruption in either synthesis or function of neuropeptides can lead to a disruption 
of individual processes and overall functioning of an organism. Based on their common 
structure, neuropeptides are grouped into families. Often the structure and function of 
members of individual families have been conserved throughout the animal kingdom. 
Several families of neuropeptides are classified as myotropic peptides based on their 
ability to affect muscle contractions. One of the largest and most extensively 
investigated families of myotropic neuropeptides is the FMRFamide (Phe-Met-Arg-Phe-
NH2)-like family of peptides (FLPs) that share structural similarity to a cardioexcitatory 
peptide FMRFamide, first isolated from molluscan bivalve, Macrocallista nimbosa clam 
by Price and Greenberg (1977). Since then, numerous peptides with the carboxyl 
terminus RFamide (Arg-Phe-NH2) were identified in vertebrates and invertebrates and 
were found to influence a variety of physiological processes such as synaptic output and 
muscle contractility (Espinoza et aI., 2000; Nassel, 2002; Nichols, 2003, Mercier et aI., 
2003). These peptides were referred to as FMRFamide-related peptides (FaRPs; Price & 
Greenberg, 1989) for over a decade. Since some RFamides (notably the myosuppressins 
and the FMRFamides) are not evolutionarily related and act on different G-protein 
coupled receptors (GPCRs), it has been recommended that the term "FaRP" be 
abandoned to avoid confusion (Scholler et aI., 2005). Therefore, in the current study, FLP 
will refer to all the peptides whose carboxyl terminus ends in FMRFamide (Phe-Met-Arg-
Phe-NH2), while the term RFamides will encompass all the other peptides including 
myosuppressins and sulfakinins. 
10 
Recently, it has been shown that the Drosophila FMRFamide-like peptide, 
DPKQDFMRFamide, enhances nerve-evoked muscle contractions (Hewes et aI., 1998) 
and synaptic transmission in the neuromuscular junction (Hewes et aI., 1998, Dunn & 
Mercier, 2006). It also modulates muscle contractility by directly inducing muscle 
contractions and increasing muscle tonus (Clark et aI., 2008), but the exact mechanisms 
through which the peptide is acting are not known. The present study was designed with 
the goal to elucidate the transduction mechanisms underlying the effects ofthis specific 
Drosophila FMRFamide-like peptide which may give us more insight in how the peptides 
of this family act in general. 
1.2 Why study molecular aspects of chemical signalling? 
Much work in all areas of biology has been devoted to studying the molecular 
mechanisms of chemical signalling, but it is often asked why one should study signalling 
networks and, more specifically, what is the significance of studying signalling networks 
in insects, such as Drosophila. First, chemical signalling mechanisms are present in the 
simplest unicellular eukaryotes (e.g flagellata), and the presence of enzymes sharing 
homology with human enzymes, such as adenylate cyclase and insulin degrading _ 
enzymes in bacteria, suggests that the roots of chemical signalling go beyond eukaryotes 
and may have evolved in prokaryotic organisms (Pertseva, 1991). Some molecular 
components of signalling pathways (i.e. adenylate cyclase and G proteins) have kept 
their main function throughout evolution, suggesting that the organisation and the 
properties of molecular particulates of chemical signalling are similar across all animal 
phyla. Hence, the knowledge gained from research on chemical signalling and its 
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molecular components in insects such as Drosophila melanogaster can be relevant for 
other animals. Secondly, disruptions or changes in chemical signalling cascades have 
been related to a number of diseases, such as atherosclerosis, asthma, diabetes, mood 
disorders and cancer. Thus, it is not surprising that chemicals involved in signal 
transduction pathways emerge as top targets for drug treatments. The identification of 
potential drug targets relies greatly on what is known about the physiology of the cell. 
Thirdly, broadening our knowledge about chemical signalling and its molecular 
components will contribute to understanding the basic physiology of organisms, and 
aid in understanding how signals flow within cells, and what are the chemical 
messengers that propagate information from one cell to another to generate specific 
activities and behaviours. 
In general, two main approaches are taken when studying the signal transduction 
pathways: pharmacological and genetic. An array of pharmacological agents has been 
identified to activate or disrupt specific molecular components of signalling pathways. 
In the genetic approach, Drosophila has been proven to be a great model system. Since 
the entire Drosophila genome is sequenced, a large number of genes that encode for 
molecular components involved in signal transduction have been identified. With the 
development of molecular techniques, many fly lines with mutations in such genes 
became available. Newer techniques can be used to overexpress or knockdown relevant 
genes in a temporal and tissue-specific pattern. 
1.3 Neuropeptides: a major class of chemical signals 
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Chemical signals are often classified into groups based on their range of action 
and their structural similarities. Chemical signals are thought to act in three ways: (a) on 
the cell that releases the chemical signal (autocrine signalling), (b) on the cell of a 
neighbouring tissue (paracrine signalling) and (c) on the cell of a distant tissue 
(endocrine signalling). Neural systems utilize all three types of signalling to affect the 
physiological function of virtually all cells through the actions of two main classes of 
chemical signals, small molecule neurotransmitters and neuropeptides (Connors, 2003; 
Kandel et aL, 1995). Small molecule neurotransmitters include amino acids and their 
derivatives (glutamate, aspartate, GABA and glycine) and monoamines (acetylcholine, 
serotonin, dopamine, epinephrine and histamine). Neurotransmitters are released from 
the nerve terminal and diffuse a short distance across the synaptic cleft (approx. 50 nm) 
to bind to receptors on a postsynaptic cell or, in some cases, to a receptor on the 
presynaptic terminal itself. Hence, they have a role in paracrine and autocrine signalling. 
Neuroendocrine signalling involves release of chemicals that act on distant targets 
(Roman, 2003; Kandel et aL, 1995). 
Neuropeptides are a diverse group of oligopeptides that co-exist and are co-
released with small molecule neurotransmitters at the synapse (0' Shea & Schaffer, 
1985; Hokfelt, 1991; Hokfelt et aL, 2000). They can act as neurotransmitters themselves, 
or they can modulate the actions of other neurotransmitters. But, many neuropeptides 
are also present in neurosecretory cells, from which they can be secreted into the 
circulatory system and carried to distant targets. Thus, neuropeptides can also function 
as hormones (Hokfelt et aL, 2000; Taghert & Veenstra, 2003). The presence of the 
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neuropeptides in the central and peripheral nervous system has been conserved from 
invertebrates to mammals (Hokfelt et aI., 2000; Deloof & Schoofs, 1990). The presence 
of some vertebrate neuropetides (e.g ~-Endorphin, insulin, gonadotropin) in unicellular 
organisms suggests that they have an enormous significance among chemical 
messengers. The great structural and functional diversity of an enormously large 
number of neuropeptides led to the grouping of peptides with common amino-acid 
sequences into families of neuropeptides. To date, crustacean and insect neuropeptides 
have been classified into 22 distinct families (Mercier et aI., 2007), although the 
discovery of novel peptides is not yet excluded. Among others, their physiological 
functions include regulation of development (preecdysis triggering hormone, 
prothoracicotropic hormone, ecdysis triggering hormone, corazonin, insulin-like peptide 
and eclosion hormone), metabolism (adipokinetic hormone), water absorption 
(corticotrophin releasing factor-like peptide, calcitonin-like diuretic hormone, 
leucokinins, arginine-vasopressin like peptide and neuroparsins) and muscle tension 
(allostatins and allotropins, cardioactive peptides, FMRFamides, leucokinins, pyrokin 
related peptides, tachykinin-related peptides, SIFamide peptide, proctolin and 
orkokinins). The mechanisms of action of neuropeptides, with the emphasis on 
myotropic peptides and more specifically FMRFamide-like peptides (FlPs), are discussed 
in more detail below. 
1.4 Signal transduction 
In general, intercellular chemical communication can be divided into several 
steps (Krauss, 2001; Roman, 2003). In some cases, a presynaptic cell secrets a 
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transmitter that binds directly to an ionotropic receptor, which directly alters the flow of 
ions through a channel. In the case of metabotropic receptors, the following steps occur: 
1. synthesis, release and transport of a chemical signal to a target cell, 
2. recognition of the signal by a receptor on the target cell, 
3. transduction of the external signal into an intracellular signal, which is 
accomplished by the activation of enzymes that produce specific second 
messengers, 
4. second-messenger-dependant activation of appropriate effectors, such as 
enzymes, ion channels and transcription factors, 
5. further transformation of reactions catalyzed by the modified effectors into a 
physiological response. 
The specificity of the cell's response to a given signal is maintained by the ability 
of the activated receptor to stimulate a specific second messenger pathway. These 
secondary messenger molecules are also important for amplifying a signal, since one 
signal molecule can induce production of a number of second messenger molecules that 
can in turn activate an even greater number of secondary effectors (Krauss et aI., 2001; 
Roman, 2003). However, the ability of a cell to respond to a specific chemical signal in 
the first place depends on whether that cell contains receptors that will recognize the 
signal. 
Two main types of receptors that have been shown to mediate the effects of 
neuropeptides are ionotropic and G-protein coupled receptors (GPCRs). Their general 
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structure and function is described below with more detailed emphasis on the receptors 
mediating responses to peptides belonging to RF-amide family. 
1.4.1 lonotropic receptors 
Classical or small molecule neurotransmitters produce very rapid responses, 
which is mainly attributed to their action via ligand-gated ion channels. Binding ofthe 
neurotransmitter to the receptor directly opens an ion channel and allows movement of 
ions across the cell membrane. An example ofthis type of receptor is the nicotinic 
acetylcholine receptor, a 290 kDa transmembrane spanning protein complex that 
functions as an ion channel. Upon the binding of acetylcholine, the receptor undergoes a 
conformational change which rotates M2 helices and opens the channel that passes Na+ 
and K+ ions across the cell membrane (Kandel et aI., 1995). 
In general, neuropeptides act via G-protein coupled receptors that are associated 
with second messenger pathways. However, the first peptide ionotropic receptor was 
identified in Helix aspersa as an amiloride-sensitive sodium channel that was shown to 
mediate responses to FMRFamide (Phe-Met-Arg-Phe-NH2) (Green et aL 1994; Cottrell, 
1997, Lingueglia et aI., 1995). Green et al (1994) reported that FMRFamide depolarized 
C2 neurons in Helix aspersa by activating two inward currents. One was a large, rapidly 
developing and rapidly desensitizing current, blocked by amiloride (an inhibitor of Na+j 
Ca2+ exchanger), suggesting that FMRFamide acts by modifying sodium currents. The 
currents were rapidly activated in inside-out patch recordings by 10 and 50 11M 
FMRFamide, even in the presence of 100 11M GDP [~-S], which inhibits binding of GTP to 
G-protein and hence, inhibits GPCR activation. These data suggested that the response 
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to FMRFamide is not mediated by G proteins and second messengers but results from 
direct binding of the peptide to sodium channels (Green et aL, 1994). The gene encoding 
for this FMRFamide receptor (FaNaCh) was then cloned from a Helix aspersa cDNA 
library using a 310 bp fragment for amiloride-sensitive epithelial Na+ channel proteins, 
ENaChs (Lingueglia et aI., 1995). The cloned FaNaCh DNA predicted a protein with two 
hydrophobic membrane spanning domains and a long extracellular loop with a cysteine 
rich region. These sections show similarity to the cloned subunits of a Na + channel 
(ENaChs) on the apical surface of epithelial cells in the kidney, distal colon and lung of 
mammals, and to an amiloride-sensitive channel of C. e/egans (Cottrell, G.A.,1997). No 
structural similarity to acetylcholine, glycine, GABA, glutamate and serotonin receptors 
was observed (Lingueglia et aL, 1995). The exact physiological functions ofthe FaNaCh 
and its role in synaptic transmission are still to be investigated. 
1.4.2 G-protein coupled receptors (GPCRs) 
Most neuropeptides exert physiological effects primarily through GPCRs. GPCRs 
are among the primary targets for drug treatments. Genes encoding GPCRs constitute a 
large group that can take up to 1-2% ofthe animal genome (Hauser et aL, 2006). In 
humans more than 1000 GPCR genes have been identified, which comprises about 3% of 
the human genome (Vauquelin & von Mentzer, 2007). GPCRs are transmembrane (TM) 
spanning proteins that consist of seven membrane spanning a helices (TM domains) 
which are interconnected with three intracellular and three extracellular loops. The 
amino (N) terminus is located on the extracellular side, whereas the carboxylic (C) 
terminus is located on the cytoplasmic side. Both the N-terminus and TM domains 
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contain amino acid sequences that are recognizable by specific ligands and, therefore, 
playa critical role in ligand binding (Vauquelin & von Mentzer, 2007; Meeusen et aL, 
2003). However, because of the large size of peptide messengers, the binding site for 
these molecules is likely to be near the N terminus (Flower et aL, 1999). The (terminus 
contains several phosphorylation sites that can playa role in receptor desensitization. 
GP(Rs have been divided into several classes based on their structural 
similarities: (a) family A, rhodopsin-like receptors, (b) family B, secretin/glucagons/VIP 
family, (c) family (, metabotropic glutamate receptors and (d) family 0, the fungal 
pheromone family. Most neuropeptides act via members of the family A, the rhodopsin-
like receptors. The members of this family share a conserved arginine sequence in the 
Asp/Glu-Arg-Tyr motif ofthe third transmembrane helix (Mercier et aL, 2007; Vauquelin 
& von Mentzer, 2007; Meeusen et aL, 2003). Only about 10 % of neuropeptides act via 
receptors of family B, which are implicated in regulating processes such as growth, 
nutrition absorption, and cell proliferation (Vauquelin & von Mentzer, 2007). The 
structural similarity of the members of this family is in the conserved cysteine residues 
and multiple glycosilation sites on the N terminus end. 
The common characteristic of all G-protein coupled receptors in the signalling 
pathway is binding to GTP-binding proteins (G-proteins), membrane-associated proteins 
that act as messengers between receptors and their target intracellular effectors. In its 
inactive state, a G protein is a heterotrimer consisting of a, ~ and y subunits. The 
a subunit is usually hydrophilic and is bound to guanosine diphosphate (GOP), while the 
~ and y subunits form a ~y complex that has a role in anchoring the G-proteins to the 
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plasma membrane. Upon binding of a ligand to its receptor, the receptor associates with 
the G-protein, which facilitates the exchange of GOP to GTP on the a subunit. This leads 
to dissociation ofthe GTP-bound a subunit from the receptor and from the ~ycomplex. 
Both, the free GTP-bound a subunit and the released ~ycomplex can associate with and 
stimulate different enzymes (e.g. adenylate cyclase (AC), guanylate cyclase (GC) and 
phospholipases A2 and C) and, hence, modulate the production of second messenger 
signals, or they can act directly on ion channels. Based on the sequence of a subunits 
and their function, G proteins are grouped into four classes: Gs, Gi/o, Gq/ ll and G12/ 13. It is 
generally accepted that the class of Gs proteins stimulate adenylate cyclase, which then 
catalyzes the conversion of ATP into cAMP and pyrophosphate (PPi), whereas the Gi class 
of proteins inhibits AC activity. Activation of the Gi/o family of G proteins also stimulates 
phospholipase A2, which further releases arachidonic acid (AA) from a membrane 
phospholipid. On the other hand, Gq/ ll proteins activate a completely different enzyme, 
phospholipase C (PLC) which cleaves phosphatidylinositol 4,S-bisphosphate (PIP2) into 
two secondary messengers, diacyl glycerol (OAG) and inositoI1,4,S-triphosphate (IP3). 
In addition to a subunits, ~ydimers can also influence several effectors. The ~y 
subunits released from activated Gi affect phospholipase C activity (Gudermann et aI., 
1996) although less potently than the a subunit (Camps et aI., 1992). ~y subunits also 
directly affect ion channels. For example activation of muscarinic, opioid or somatostatin 
receptors and subsequent activation of G/o G-proteins leads to the activation of K+ 
channels and to the inhibition of Ca2+ channels through direct binding by the ~y complex 
(Oascal, N.,2001; Jiang & Bajpayee, 2009). 
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1.4.2.1 RFamide GPCRs 
RFamide and FLP GPCRs have been identified in several animal phyla. A GPCR 
(GRL106) activated by the RFamide cardioexcitatory peptide LyCEP (TPHWRPQGRF-NH2) 
was cloned from the mollusc Lymnaea stagnalis (Tensen et aL,1988). Eleven GPCRs that 
respond to RFamide ligands were identified from the nematode C. e/egans (McVeigh et 
aL 2006). Radioligand binding assays revealed that the RFamide receptor from the optic 
lobe of squid (Loligo pea/ei) has a high binding affinity for FMRFamide and is coupled to 
Gs protein (Chin et aL1994). Similarly, Wang et aL (1995) found evidence that 
YDVDHVFLRFamide inhibitory effects on locust oviducts are mediated via GPCR since the 
increase in concentration of GTPyS, a non hydrolyzable GTP analog, reduced the binding 
of the receptors to YDVDHVFLRFamide. The failure of cholera toxin and pertusis toxin to 
affect the specific binding of the receptors to YDVDHVFLRFamide suggested that this 
receptor is not coupled to either Gs or Gi (Wang et aL, 1995). 
GPCRs for D. me/anogaster myosuppressins (Drm-MS), sulfakinins (Drm-SK) and 
FMRFamides (FLPs) have also been identified and cloned . cDNA sequences revealed 
that the myosuppressin GPCR (DMSR-1) gene CG8985 is 3,286 nucleotides (nt) long and 
consists of five exons and four introns, while the myosuppressin GPCR (DMSR-2) gene 
CG13803 is 2,618 nt long and has four exons and three introns (Egerod et aL, 2003). The 
cDNA ofthe Drosophila FMRFamide receptor (DFR) gene CG2114 is 3,061 nt long, 
consisting of 2 exons and 1 intron (Cazzamali & Grimmelikhuijzen, 2002). Northern blot 
analysis revealed differences between the mRNA expression of cloned receptors, DMSR-
1 (CG8985), DMSR-2 (CG13803) and DFR (CG2114). While Egerod et al (2003) reported 
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very weak mRNA expression of the two DMS receptors in embryos, larvae, and pupae, 
Cazzamali and Grimmelikhuijzen (2002) found that the DFR transcript, present in all of 
the developing stages of Drosophila, had the most pronounced expression in larvae and 
adults. In adult flies, DMSR-1 and DMSR-2 transcripts were strongly expressed in the 
head, but only DMSR-2 was present in the adult body. More detailed information about 
the DFR expression pattern in organs of wandering stage larvae was obtained with RT-
PCR analysis, which revealed that the receptor is present in several Drm larval organs, 
including trachea, brain, gut, fat body, and Malpighian tubule (Meeusen et aI., 2002). 
The effects of a number of different peptides on transfected Chinese hamster 
ovary (CHO) cells expressing cloned DMSR-1, DMSR-2 or DFR were tested using an 
aequorin bioluminescence assay that detects changes in intracellular Ca2+. Two 
independent studies, Meeusen et al. (2002) and Cazzamali and Grimmelikhuijzen (2002) 
tested the effects of FLPs and other RFamides on the DFR expressed in CHO cells. Both 
studies revealed that the intrinsic Drosophila FMRFamide peptides activated the DFR 
receptor, although there are discrepancies in the order of their potency. In both studies, 
it was found that Drm-FMRFamide-S (PDNFMRF-NH2) was the most potent in activating 
DFR (Table 1). Following the PDFMRFamide, intrinsic FMRFamides activated DFR 
receptor in the following order (from highest to the lowest potency,): 
DPKQDFMRFamide > TPAEDFMRFamide> SPKQDFMRFamide, SDNFMRFamide according 
to Cazzamali & Grimmelikhuijzen (2002L or SDNFMRFamide > DPKQDFMRFamide > 
SPKQDFMRFamide > TPAEDFMRFamide as per Meeusen et al (2002). (Table 1). It is 
interesting to note that SAPQDFVRSamide failed to activate the receptor (Cazzamali & 
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Grimmelikhuijzen, 2002) suggesting that the RFamide sequence at the N terminal is 
necessary for the peptide-receptor binding to occur. 
The FMRFamide receptor can also bind peptides that are structurally similar to 
FMRFamides but with ECso values higher than those peptides containing FMRFamide N 
terminal sequence (e.g. 2 x 10 -7 M for Drm-MS; Meeusen et aI., 2002; 
Table 1. FLP effects on dFMRFamide GPCR expressed in Chinese hamster ovary cells 
Peptide Sequence 
Drm-FMRFamide-l DPKQDFMRF-NH2 
Drm-FMRFamide-2 TPAEDFMRF-NH2 
Drm-FMRFamide-3 SDNFMRF-NH2 
Drm-FMRFamide-4 SPKQDFMRF-NH2 
Drm-FMRFamide-S PDNFMRF-NH2 
Drm-SK-l FDDYGHMRF-NH2 
Drm-SK-2 GGDDQFDDYGHMRF-NH2 
Drm-MS TDVDHVFLRF-NH2 
FMRFamide FMRF- NH2 
RFamide RF-NH2 
a) Meeusen et aI., 2002 
b) Cazzamali & Grimmelikhuijzen, 2002 
not tested 
ECso (nM) "'ECso(nM) 
(a) (b) 
2.0 3 
2.8 9 
1.9 500 
2.5 9 
1.8 0.9 
38 
105 
91 200 
28 6 
n.a 
(>10uM) 
Cazzamali & Grimmelikhuijzen, 2002). Hence, the FMRFamide receptor appears to be a 
true FMRFamide receptor that can differentiate between different N terminal amino 
acid sequences and is less likely to be a genuine receptor for other -RFamide peptides, 
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although it is possible that peptides such as Drm-MS may bind to the receptor under 
unusual physiological conditions with high peptide levels. 
CHO cell lines transfected with cDNA coding for either DMSR-1 (CG8985) or 
DMSR-2 (CG13803) responded to DMS with an ECso of 4 x10 -8 M, whereas other 
peptides, crustacean cardioactive peptide capa-1, -2, and -3,corazonin, adipokinetic 
hormone, tachykinin-3, short neuropeptide F-1, ecdysis triggering hormones-1 and -2, 
pigment dispersing hormone, pyrokinin-2, drostatins-A4 -B2, and -C, and FMRFamide, 
failed to induce a response in the concentrations up to 10-6 M or lO-s M (Egerod et aI., 
2003). Similar results were reported by Johnson et al. (2003), where simultaneous 
transfection of HEK-293 cells with a ~-arrestin molecule tagged with a green fluorescent 
protein (Barr-GFP) and the GPCR of interest was used as a method to visualize the 
activation of GPCRs. This method is based on the desensitization mechanisms shared by 
all GPCRs, which assumes that all GPCRs are inactivated by two types of proteins, GPCR 
kinases (GRKs) and ~ -arrestins. When the receptor is in its inactive state, ~-arrestins are 
diffused in the cytoplasm, but upon the activation of GPCR the ~ -arrestins are recruited 
and translocated to the membrane. The cells expressing C613803 responded to 1IJ.M 
DMS by the translocation of Barr-2, but did not respond to 1IJ.M DPKQDFMRF-amide. 
Comparing the actions of DM and DPKQDFMRFamide, Johnson et al (2003) found Drm-
MS to be more potent in inhibiting forskolin-induced cAMP production in C613803- HEK-
293 and C6898-HEK-293 cells (ECso: 1.7 x 10-10 M and 1.8 x 10-9 M respectively) than 
DPKQDFMRFamide (ECso: 4.5 x 10-9 M and 1.3 x 10-8 M respectively). The ability of 
peptides to inhibit cAMP production also suggests that DMSRs may be coupled to G/o 
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proteins. Cells expressing the dFMRF-amide receptor encoded by CG2114 showed Barr2-
GFP translocation in response to the 111M DPKQDFMRF-amide and Drm-MS, which 
would be predicted based on the result reported by Cazzamali and Grimmelikhuijzen 
(2002) (Table 1). However, the dose dependent effects of these peptides on ~ -arrestin 
translocation were not established, and, therefore no inference can be made about the 
relative sensitivities ofthe CG2114 to two different peptides. 
Finally, the Drosophila SK receptor (DSKR-1) has also been cloned and 
pharmacologically characterized. Sulphated [Leu7]-DSK-1 increased the Ca2+ signal in 
HEK-293 cells transfected with DSKR1 in a dose-dependent manner (ECso= 5.3 nM) 
(Kubiak et aL, 2002). The effect was not affected by pertussis toxin incubation, which 
suggests that this receptor does not activate Gila proteins. 
To summarize, RFamides can exert their effects via both GPCRs and ionotropic 
receptors. It appears that three different groups of RFamides (Drosophila FMRFamides, 
myossuppresins and sulfaknins) act through different GPCRs, all of which were cloned 
and identified in Drosophila (Meeusen et aL, 2002, Cazzamalli et aL, 2002, Johnon et ai, 
2002, Kubiak, 2002, Egerod et aL, 2003). To date, however, functional characterization 
of these GPCRs was confined to cell cultures, either Chinese hamster ovary cells or 
Human embryonic kidney cells. Studies using this approach reported that one of these 
GPCRs, FR (gene CG2114), binds with high affinity to FMRFamides, while it was less 
sensitive to other RFamide peptides (Meeusen et aL, 2002; Cazzamali & 
Grimmelikhuijzen, 2002). It follows that ifthe physiological effect of DPKQDFMRFamide 
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on the larval body wall muscle contracture was mediated by a GPCR, it is likely to be 
mediated by the DFR. 
1.5 Myotropic neuropeptides 
Approximately half of the identified insect neuropeptides have stimulatory or 
inhibitory effect on muscle tissue and are referred to as myotropic neuropeptides 
(Mercier et aL, 2007; Taghert & Veenstra, 2003). Although, a large proportion of 
research has been devoted to investigating the mechanisms of peptide-induced 
modulation of insect muscle contractility, the knowledge is still very limited. Some of the 
most investigated myotropic neuropeptides include crustacean cardioactive peptide, 
proctolin and FLPs, and in the next section I will briefly outline their physiological effects 
on crustacean and insect muscles and what is known about the mode of their action. 
1.5.1 CCAP 
Crustacean cardioactive peptide (CCAP; Pro-Phe-Cys-Asn-Ala-Phe-Thr-Gly-
Cys-amide) was first isolated as a crustacean cardiostimulatory peptide of the crab, 
Carcinus maenas (Stangier et aL, 1987). Subsequently, it was shown that CCAP 
stimulates contractions of the locust spermathecal (da Silva & Lange, 2006) oviduct 
(Donini et aL, 2001) and hindgut (Donini et aL, 2002;Stangier, 1988) tissues. CCAP 
increased the amplitude of nerve-evoked contractions, basal tonus, and the frequency 
of spontaneous contractions of the spermatheca (da Silva & Lange, 2006) and oviducts 
(Donini et aL, 2001, 2002). In the absence of nerve stimulation, spermathecal and 
oviduct muscles responded to CCAP with a threshold concentration of approximately 1 
nM; the maximum effect occurred at 100 nM for spermathecal muscles and 500 nM for 
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oviduct tissue (da Silva & lange, 2006; Donini et aL, 2001). CCAP -induced contractions 
in locust oviducts were abolished in calcium-free saline containing 0.1 mM EGTA (a 
calcium chelator) and in saline containing 20 mM cobalt chloride, (a calcium channel 
blocker) indicating that extracellular Ca2+ is necessary for the response to occur (Donini 
et aL, 2002). When applied individually, l-type and T-type calcium channel blockers 
reduced the tonic component of CCAP-induced contractions by approximately 30-50%. 
This suggests that the peptide induces Ca2+ entry via voltage-gated Ca2+ channels (VGCC). 
However, the peptide increased the tonus of oviduct muscles even after the VGCC were 
activated via high potassium saline-induced membrane depolarization, which suggests 
that, in addition to VGCCs, the peptide also uses non-voltage gated Ca2+ channels (Non-
VGCCs) (Donini et aL, 2002). The peptide also stimulates Ca2+ release from internal 
stores, since 10 ~M TMB-8, an intracellular calcium antagonist, reduced the tonic 
component of 10-8 M CCAP-induced oviduct contractions by 30-35 % and delayed the 
time to reach the contraction peak (Donini et aL, 2002). 
1.5.2 Proctolin 
Proctolin is a penta peptide (H-Arg-Tyr-leu-Pro-Thr-Oh) isolated and identified as 
a myostimulatory peptide in the hindgut of the cockroach Periplaneta americana (Brown 
& Starrat, 1975). Proctolin is associated with controlling visceral and skeletal muscle 
contractility in insects (Orchard et aL, 1989) and hindgut tissue of crustaceans (Mercier 
et aL, 2007; Mercier & lee, 2002). 
A large number of studies focused on elucidating the mechanism underlying 
proctolin myotropic action. In the mandibular closer muscles of the locust, Locusta 
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migratora, proctolin was shown to increase amplitude of neurally-evoked contractions 
and cause a sustained increase in tonus, but could not evoke contractions in resting 
muscle (Bains & Downer, 1991). The magnitude of this response increased with 
increasing frequency of stimulation from 1 to 8Hz, suggesting that the peptide effects 
depend on the level of depolarization (Bains & Downer, 1991). Similar dependence on 
depolarization was also observed in locust oviducts (Noronha & Lange, 1997). Proctolin 
also increased tonic contractions in the muscles pre-treated with glutamate, indicating 
that the peptide acts directly on the muscle tissue (Bains & Downer, 1991). This 
coincides with the evidence that proctolin increases the frequency and amplitude of 
myogenic contractions of the oviducts (0.5-5nM; Lange et aI., 1987) and foregut muscles 
(10-8 to 2 X 10-6 M: Gray et aL, 1994) of Locusta migratoria and single muscle fibres of 
the marine isopod (/dotea) abdominal extensor muscles (Erxleben et aL, 1995). 
The enhancement of both nerve evoked (Bains & Downer, 1991) and myogenic 
contractions (Lange et aI., 1987; Wegener & Nassel, 2000) by proctolin was abolished in 
calcium free saline and partially reduced in the presence of VGCC inhibitors, which 
suggests that proctolin exerts its effects via influx of extracellular Ca2+ through voltage 
gated Ca2+ channels. It has been proposed that the action of the proctolin on the locust 
oviducts (Lange et aL, 1987) and the hindgut of a cockroach (Cook and Holman, 1985) 
involve non-voltage-gated Ca2+ channels. 
In locust extensor tibialis muscle, iontophoretic application of proctolin at 
concentrations higher than 5 x 10 -10 M depolarized the membrane (May et aL, 1979), 
however, the stimulatory effects of proctolin on locust mandibular muscle (Bains and 
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Downer., 1991) and crayfish tonic flexor muscle (Bishop et aI., 1987) were not 
accompanied by muscle depolarization. Tension recording and currrent-ciamp 
recordings from single, isolated, abdominal extensor muscle fibres of the marine isopod 
Idofea baltica revealed that myostimulatory effects of proctolin are associated with it's 
ability to increase membrane input resistance (by approx.25%). The increase in input 
resistance was accomplished through reduction of the activity of non-voltage dependent 
K+-permeable channels by approximately 63% (Erxleben, 1995). 
The effect of proctolin on membrane input resistance and contraction amplitude 
was mimicked in the presence of membrane-permeable cAMP analog 
dibutyryladenosine 3', 5'-cyclic monophosphate (db-CAMP, 10-4 M), and inhibitor ofthe 
cAMP phosphodiesterase, 3-isobutyl- 1-methyl-xanthine {lBMX, 10-4 M) (Erxleben, 1995) 
which suggest that cAMP and PKA (cAMP-dependent protein kinase) may be involved in 
mediating proctolin's myotropic effects. The action of proctolin is also likely to be 
mediated by the phospholipase C (PLC) pathway since proctolin increased the 
production of 1,4,5-inositoltrisphosphate (IP3) from the foregut homogenates ofthe 
locust s. gregaria (Hinton & Osborne, 1995) and locust mandibular closer muscle 
(Baines et al.,1990). Proctolin-induced contractions in the hyperneural muscle ofthe 
cockroach Periplaneta americana were reduced by TMB-8, an non-selective blocker of 
intracellular Ca2+ release, thapsigargin, a blocker ofthe Ca2+ -ATPase ofthe sarcoplasmic 
reticulum, and ryanodine (10 mM), a ryanodine receptor antagonist which suggests that 
IPrindependent Ca2+ release from the sarcoplasmic reticulum also plays a critical role in 
proctolin-induced contractions (Wegener & Nassel, 2000). 
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1.5.3 RF-amide peptides 
Based on their C terminal sequence, insect RFamides are grouped into 
FMRFamide, HMRFamide, FlRFamide, RVRFamide and RlRFamide peptides (Nassel et 
aL, 2002; Mercier et aL, 2007; Orchard et aL, 2001). The last two sub-groups, also 
referred to as neuropeptide F, are involved in reproduction, feeding and ecdysis 
behaviours (Mercier et aL, 2001) and will not be dealt with in this review. In Drosophila, 
three groups of RFamide peptides, FMRFamides, myosuppressins (DMS; FlRFamides) 
and sulfakinins (DSK; HMRFamides) are encoded on separate genes, referred to as 
dFMRFamide, Dms and Dsk. These genes produce inactive precursor polypeptides that 
are further subjected to a series of posttranslational modifications to become bioactive 
peptides (Vanden Broeck, 2001; Nichols, 2003). The Dms gene encodes for one copy of 
myosuppressin (TDVDHVFlRFamide), and the Dsk gene encodes for three sulfakinins 
(DSK-O, DSK-I and DSK-II) (Vanden Broeck, 2001; Nichols, 2003). The dFMRFamide gene is 
a single copy gene that was first cloned by Nambu et aL (1988). It consists of two exons 
(106 and 1352 base pairs) and one intron (2500 base pairs) (Nambu et aL, 1988; 
Schneider & Taghert, 1988). This gene encodes for 10 copies of FMRFamide-containing 
peptides (5 copies of DPKQDFMRFamide, 2 copies of TPAEDFMRFamide, and one copy 
each of SDNFMRFamide, SPKQDFMRFamide and PDNFMRFamide) and three other 
peptides (SVQDNFMHFamide, SAPQDFVRSamide and MDSNFIRFamide). 
1.5.3.1 Distribution 
RFamide-like immunoreactivity is present in central and peripheral nervous 
systems, as well as in neurosecretory cells in crustaceans (crayfish and lobster; Mercier 
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et aI., 2001) and insects (Orchard et aI., 2001; Nassel et aI., 2002), suggesting that 
RFamides have neurotransmitter and neurohormonal functions. Approximately 44 out of 
10000 Drosophila neurons express the dFMRFamide gene, including interneurons, 
motor neurons and neurohaemal neurons (Schneider et aI., 1993a,b). The expression of 
antiserum raised against FMRFamide showed that RFamides are present throughout the 
central nervous system (subesophageal ganglion, thoracic ganglia, the abdominal 
ganglia, medial and lateral protocerebrum, optic lobes and subesophageal ganglion) and 
the gastrointestinal system in all stages of Drosophila development (Nichols et aI., 
1999a). Using antisera raised to the specific N-terminus of DPKQDFMRFamide, 
SDNFMRFamide, and TPAEDFMRFamide peptides in a triple immunolabeling 
experiment, McCormic et aL(1999) showed that the expression patterns of these 
peptides encoded in the Drosophila FMRFamide gene are very distinct and they do not 
overlap. This suggested that the expression of FMRFamide peptides may be regulated at 
the posttranscriptional level. MALDI-TOF mass spectrometry profiling of the Drosophila 
larvae neurohaemal organs revealed the presence of DPKQDFMRFamide, 
TPAEDFMRFaamide, SDNFMRFamide, SPKQDFMRFamide, PDNFMRFamide, 
SAPQDFVRSamide and MDSNFIRFamide in the thoracic perisympathetic organs, a site of 
neurohaemal release from the thoracic and abdominal ganglia (Wegener et aI., 2006). 
Drosophila myosuppressin (TDVDHVFLRFamide; DMS) was found in ring glands 
(Wegener et aI., 2006), a structure that consists of three neurohemal organs, the 
corpora cardiaca, corpora allata and the prothoracic gland. The expression of Drosophila 
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FMRFamide-containing peptides and Drosophila myosuppressin in neurohemal organs 
further supports the idea that these peptides act as neurohormones. 
1.5.3.2 Activity 
Diverse physiological roles of RFamides are mostly related to their ability to 
modulate the contracture of different muscles (eg. heart, visceral and somatic muscles). 
This peptide-induced change in the muscle contractility can result from peptides acting 
on multiple targets, including central pattern generating circuits (CPGs), motor neurons, 
neuromuscular junctions and muscle fibres (Kravitz, 1988). 
RFamides have been found to affect the heart rate in several animal species and 
can have both, inhibitory and excitatory effects. FLRFamides in lobster (TNRNFLRFamide; 
Worden et aL, 1995) crayfish (DRNFLRFamide and NRNFLRFamide; Skerrett et aL, 1995) 
and crab (NRNFLRFamide SDRNFLRFamide, and GYNRSFLRF ; Fort et aL, 2007) increase 
the frequency and amplitude of muscle contractions in isolated hearts which may be 
partially caused by modulation of the impulse frequency in the cardiac motor neurons 
(Mercier et aL, 2003). FMRFamide has stimulatory effect on the heart of L. stagnalis, since 
the peptide increases the frequency, amplitude and tonus of heart contractions in a dose 
dependent manner, with a threshold of approximately 100 pM and a maximum response 
occurring at l~M (Willoughby et aL 1999b). In vivo recordings revealed that Drosophila 
FMRFamides and OMS affect heart rate as well, although the effects were inhibitory. 
SONFMRFamide (1 ~M and 10 ~M injections) decreased the frequency of heart 
contractions to approximately 70-80% of basal heart rate in pupae and adult Drosophila 
flies within the first minute of peptide application, while DPKQOFMRFamide and 
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TPAEDFMRFamide (10 11M) had no effect on the contractility rate of pupal and adult heart 
muscle (Nichols et aI., 1999b). In contrast, Johnson et al. (2000) reported that 
DPKQDFMRFamide reduced pupal heart rate in a dose-dependent manner with an ECso at 
approximately 0.3 11M. PDNFMRFamide also reduced the heart rate with an ECso of 
approximately 80 11M. Taken together, results suggest that FMRFamide containing 
peptides have inhibitory effects on heart contractions, however, the strength of the 
inhibitory effects differ among these peptides. The observed difference in the potency of 
the peptide's actions could be explained by the difference in their N-terminus sequences, 
which may be a critical factor for determining their binding affinities for the receptor 
(Table1). The other plausible reason for the difference in their effects is that they are 
binding to different receptors. Effects of DMS on pupal heart rate measured in vivo were 
more pronounced than those of FMRFamides {Merte & Nichols, 2002; Nichols, 2006}. 
Within 30 s after the injection of 111M TDVDHVFLRFamide, the heart rate dramatically 
decreased to approximately 30 % of the basal level. The initial decrease in the frequency 
of muscle contractions was followed by a partial recovery to approximately 80 % of the 
basal heart rate that was sustained throughout the 10 min recording period (Nichols, 
2006). A recent study by Nichols and colleagues {2009} reported that sulphated 
Drosophila sulfakinins (DSK I; FDDYGHMRFNH2 and DSK II: GGDDQFDDYGHMRFNH2) 
increased the frequency of larval, pupal, and adult heart contractions. 
RFamides also affect the gut activity of crustaceans and insects. Lobster 
(TNRNFLRFamide and SDRNFLRFamide; 1 nM - 0.1 11M) and cockroach 
(pQDVDHVFLRFamide; 0.1-10 11M) FLRFamides enchanced spontaneous hindgut 
32 
contractions in crayfish, P.clarkii (Mercier at aL, 1997). In contrast, DMS and 
FMRFamides had inhibitory effects on Drosophila gut contractility. The average rate of 
adult crop motility was reported to be approximately 47 contractions/ min (Kaminski et 
aL, 2002). 111M (Kaminski et aL, 2002) and 100 11M (Duttlinger et aL, 2002) DMS 
completely stopped movement of the adult crop within 1 min of peptide application. 
Recovery of this effect was not observed during the 10 min recording period. The effect 
of FMRFamides on crop contractility was less dramatic. The maximal reduction to 
approximately 65% of basal crop contractility was observed within 2 minutes after 111M 
SDNFMRFamide application (Kaminski et aL, 2002). Application of 100 11M 
TPAEDFMRFamide decreased the frequency of spontaneous crop contractions in the 
adult to 40% ofthe basal rate within 1 min (Duttlinger et aL, 2002). Recovery of 
approximately 20% of crop movement was noted in 10 min. In contrast to the effects of 
TPAEDFMRFamide, 100 11M DPKQDFMRFamide and 100 11M of SDNFMRFamide had no 
effect on the frequency of spontaneous crop contractions (Duttlinger et aL, 2002). Using 
an in vivo assay, Palmer et al (2007) recorded the frequency of adult crop contractions 
and larval anterior midgut in response to 100 11M DSKO (NQKTMSFNH2). DSKO 
decreased the frequency of the adult crop contraction rate to 34 % of the basal 
contraction rate, but it had no effect on larval gut contractions (Palmer et aL, 2007). 
In addition to cardiac and gut muscles, crustacean skeletal muscles are also 
targets for RFamide peptides. For example, TNRNFLRFamide potentiates nerve-evoked 
contractions in the opener muscle of lobster (Worden et aL, 1995) and crayfish deep 
abdominal extensor muscles (Mercier et aL, 1990). Similar excitatory effects of 
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FMRFamides on nerve-evoked contractions were obtained in Drosophila larval body wall 
muscles (Hewes et aI., 1998). Five FMRFamides (DPKQDFMRFamide, TPAEDFMRFamide, 
SDNFMRFamide, SPKQDFMRFamide and PDNFMRFamide) enhanced nerve-evoked 
muscle tonus with the threshold of approximately 10 nM (ECso :25 nM)(Hewes et 
al.,1998). Excitatory effects on nerve-evoked contractions appear to involve both, 
presynaptic and postsynaptic mechanisms. A presynaptic mechanism would involve 
peptide acting on the presynaptic terminal to enhance or facilitate the release of 
neurotransmitters that will, in turn, result in activation of a larger number of 
postsynaptic receptors, and, enhance the response of the muscle cell. DRNFLRFamide , 
for example, increases the number of quanta of transmitter released from nerve 
terminals onto deep abdominal extensor muscles without changing the amplitude of 
quantal synaptic currents (Skerrett et aI., 1995). Hewes et al. (1998) showed that 0.1 ~M 
DPKQDFMRFamide enhanced the amplitude of excitatory junctional currents (EJCs) by 
50% in Drosophila muscle fibres. In addition to affecting EJCs, DPKQDFMRFamide (1 ~M) 
significantly increased the amplitude of excitatory junctional potentials (EJPs) in larval 
muscles by approximately 20 % (Dunn & Mercier, 2005). This effect was neuron specific. 
EJPs elicited by stimulating one motor neuron (lb) were enhanced, but EJPs elicited by 
another neuron (ls) were not altered, even though EJPs occurred in the same muscle 
fibre. As with the effects of DPKQDFMRFamide on nerve-evoked muscle contractions, 
the effects on synaptic potentials were dose-dependent, with a threshold of 
approximately 10 nM and a maximal effect at approximately 1 ~M (Dunn & Mercier, 
2005). 
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The postsynaptic mechanism, on the other hand, assumes direct action of 
peptide on the muscle cell by binding to the receptor and activating a cascade of events 
that lead to an initiation of contractions. Postsynaptic actions of RFamides were 
confirmed in crustacean and insect models. In P.clarkii, for example, DRNFLRFamide 
increased the tonus of superficial extensor muscles of the crayfish abdomen, even in the 
presence of a spider toxin, that blocks glutamate receptors (Quigley & Mercier, 1997) 
and potentiated the contractions evoked by direct electrical stimulation ofthe deep 
abdominal extensor muscles after removing the synaptic terminals by digestion with 
collagenase (Mercier et aL, 2003). In Drosophila, DPKQDFMRFamide induced larval body 
wall muscle contractions in the absence of nerve stimulation (Clark et aL, 2008). This 
effect was noted even after glutamate receptors were desensitized with 7 mM 
glutamate, which suggests that DPKQDFMRFamide- induced muscle contractions do not 
result from increasing glutamate release from the presynaptic terminals (Clark et aL, 
2008) and thus, that peptide acts directly on muscle fibres to initiate muscle contraction. 
However, the possibility of peptide increasing spontaneous release of neurotransmitters 
other than glutamate has not been excluded. The intracellular mechanisms mediating 
the postsynaptic response are still largely unknown. 
1.5.3.3 Mechanisms of action 
There is compelling evidence that several second messengers may be involved in 
mediating the stimulatory effects of RFamides on synaptic output. FLRFamide and 
FMRFamide-induced enhancement in EJP amplitude at the crayfish (Noronha & Mercier, 
1995) and Drosophila (Dunn & Mercier, 2005) neuromuscular junctions was abolished in 
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the presence of CaMKII (Ca2+/calmodulin-dependent protein kinase, type 2) inhibitors. 
Protein kinase C (PKC) inhibitors potentiated the DRNFLRFamide -induced initial rise in EJP 
amplitude by approximately 15 % but also increased the rate of washout effects, 
suggesting that the PLC pathway plays a critical role in maintaining the stimulatory effect 
of peptide on neurotransmitter release, even after the peptide has been removed 
(Friedrich et aL, 1998). PKA and PKG (cGMP-dependent protein kinase) inhibitors, (Rp-
cAMPS and Rp-8-pCPT-cGMPS) reduced the effects of DRNFLRFamide on EPSP amplitude 
by approximately 75% and 40%, respectively. However, when both inhibitors were applied 
together, the combination completely abolished the ability of the peptide to enhance 
EPSP amplitude (Badhwar et aL, 2006). Thus, presynaptic modulation appears to involve 
up to four protein kinase enzymes. In Drosophila, the mechanism by which 
DPKQDFMRFamide modulate synaptic output was shown to involve Ca2+ regulation. Using 
the calcium-sensitive calcium fluorophore, Oregon Green 488, Klose et aL (2010) showed 
that single stimuli applied to the nerve cause a transient rise of Ca2+ -induced fluorescence 
(Ca2+ peak amplitude) in individual tonic-like nerve terminals of axon lb. The amplitude 
ofthese stimulus-evoked Ca2+ peaks was enhanced by O.ljlM DPKQDFMRFamide, but the 
basal Ca2+ levels remained the same. Xestospongin (100 nM), an IP3 receptor inhibitor and 
ryanodine (100 jlM), which inhibits ryanodine receptors (RYR), abolished the ability ofthe 
peptide to increase the amplitude of stimulus-evoked Ca2+ peaks (Klose et aL, 2010). The 
same result was obtained with IP3 and RYR mutants (Klose et aL, 2010). In addition, the 
peptide's effects on EJP amplitude were also abolished in these mutants (Dunn, T., 2003; 
Klose et aL, 2010). Taken together, these data suggest that the peptide augments peak 
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Ca2+ levels in synaptic terminals via action on IP3 receptors and ryanodine receptors 
associated with internal Ca2+ stores, and the resulting enhancement of CaMKIl increases 
neurotransmitter release. The consequent increase in EJP amplitude would contribute to 
the observed enhancement of nerve-evoked contractions. 
Although most of the identified RFamides exert either inhibitory or stimulatory 
actions on muscle contractions, not much is known about the mechanisms underlying 
their effects on excitation-contraction coupling. 
FMRFamide increased the rates of Ins(1,3,4)P3 production in the L.stagnalis 
heart tissue (1 ~M FMRFamide; Willoughby et aL, 1999b) and the tentacle retractor 
muscles of Helix aspers a (100 ~M FMRFamide; Falconer et aL, 1993). In contrast, pGlu-
Asp-Pro-Phe-Leu-Arg-Phe-NH2 (pQDPFLRFamide), which was shown to relax the tentacle 
retractor muscles, did not affect InsP3 levels (Falconer et aL, 1993). Application of IP3 to 
DMSO permeabalized isolated heart increased beat frequency (3S±S% increase from 
controls) and muscle tonus (Willoughby et aL, 1999b). Neomycin, a PLC inhibitor, 
reduced the cardioexcitatory effects of FMRFamide and the ability of FMRFamide to 
stimulate Ins(1,4,S)P3 production. Together, these data provide evidence that IP3 is an 
important factor in mediating the excitatory effects of FMRFamide peptide on muscle 
contractions. 
However, FMRFamide also increased AC activity in heart tissue of L.stagnalis 
(Willoughby et aL, 1999a). FMRFamide increased the rate of cyclic AMP production by 
approximately 3 fold from the control levels. The threshold concentration necessary to 
produce an increase in the rate of cyclic AMP production was approximately 10 nM, 10 
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fold higher than that observed with IP3 production, which may suggest that cAMP is not 
the primary second messenger mediating peptide's effects. The cardioexcitatory effects of 
FMRFamide were mimicked by a membrane-permeable cyclic AMP analogue (8-bromo-
cyclic AMP) and an AC activator (forskolin) (Willoughby et aLI 1999a). Thus, the 
FMRFamide's myoexcitatory effects appear to be mediated by two different second 
messengers systems, cAMP and PLC-IP3. 
The effects of RFamides on muscle membrane properties are variable. In the 
crayfish deep abdominal extensor muscle, DRNFLRFamide and SDRNFLRFamide do not 
alter the input resistance, whereas TNRNFLRFamide and NRNFLRFamide increase input 
resistance by approximately 15 % (Mercier et aLI 1990; Skerrett et aLI 1995). The ability 
of peptide to increase input resistance suggests that it may be acting directly on the 
muscle tissue. Two-electrode voltage clamp recordings from the jumping muscle (m. 
extensor tibiae) of the locust s. gregaria revealed that the octopus peptide 
YGGFMRFamide, decreased the resting membrane conductance and the 
hyperpolarization-activated K+ current by 38% and 46%, respectively (Walther, 1984). 
YGGFMRFamide also potentiated neurally-evoked muscle contractions by 2-3 fold 
(Walther, 1984). Hence, reducing the rectifying K+ current may result in an increase in 
membrane excitability, wh ich would account for the excitatory effects of this 
neuropeptide. 
As seen with proctolin and CCAP-induced contractions, DPKQDFMRFamide-induced 
muscle contractions in D. melanogaster were also abolished in Ca2+ free saline (Clark et aLI 
2008). In addition, L-type calcium channel inhibitors, nifedipine and nicardipine, 
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completely abolished the ability of DPKQDFMRFamide to increase Drosophila body wall 
muscle tonus (Clark et aI., 2008), suggesting that the peptide requires the influx of 
extracellular calcium via VGCC to induce muscle contractions in the absence of nerve 
stimulation. Hence, the model of action of DPKQDFMRFAmide is proposed (Fig 1A) in 
which the peptide acts on and activates the membrane bound receptor which in turn 
leads to an activation of VGCC, influx of calcium and activation of cascades of events 
leading to muscle contraction. However, the molecular mechanisms that bridge the gap 
between the binding of DPKQDFMRFamide to a receptor, including the identification of 
the receptor itself, and the influx of Ca2+ through L-type calcium channels are not known 
(Fig 2B). 
1.6 Insect muscles 
Larval locomotion is under the control of central pattern generators and consists of 
repeated peristaltic contraction waves that propagate from the head towards the 
posterior end of the larvae. This is accomplished by alternating between contracting the 
longitudinal muscles and oblique muscles in order to shorten and lengthen the body along 
its longitudinal axis, respectively (Peron et aI., 2009). 
All insect muscles are striated and each muscle fibre consists of the cell membrane 
(sarcolemma) and the inner sarcoplasm. In Drosophila, each larval hemisegment contains 
30 supercontractile muscle fibres whose actin and myosin filaments are organized in a 
fashion similar to vertebrate striated muscles (Goldstein & Burdette, 1971). Each muscle 
is attached to an apodeme, which serves as a functional skeleton attaching the muscle 
fibre to the cuticle (Budnik and Gramates, 1999). 
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In vertebrate skeletal muscles, contraction is elicited by release of calcium from an 
intracellular store (the sarcoplasmic reticulum) through channels sensitive to ryanodine 
(Randall et aL, 2002). The mechanisms involved in excitation-contraction coupling in 
Drosophila larvae are still under investigation. The trigger for contraction involves an 
increase in intracellular calcium concentration via influx of calcium through VGCC, which 
then leads to calcium-induced calcium release (ClCR) from internal stores, presumably via 
opening of ryanodine receptor (RYR) channels in the membrane of the sarcoplasmic 
reticulum (SR) (Wang et aL, 2003). Body wall contraction propagation (locomotion) was 
completely inhibited in Drosophila larvae that ingested ryanodine at a dose known to 
completely inactivate RYRs (100 mM) and was severely reduced in RyR mutant larvae 
(Sullivan et aL, 2000), suggesting that RyRs indeed playa crucial role in larval muscle 
contraction. The effects of another protein found on the SR membrane that is involved in 
sequestering intracellular calcium, a sarcoplasmic/endoplasmic reticulum calcium pump 
(SERCA), on muscle contractions in Drosophila is largely unknown. 
Similarly to vertebrate muscles, invertebrate muscles have a well developed T-
tubule system (transverse tubular system) consisting of deep invagination of the muscle 
cell membrane into the muscle fibre, which enables the depolarization of the membrane 
to spread deep into the muscle (Rosomer and Stoffolano, 1994). In some invertebrate 
fibres, the influx of calcium through the cell membrane and T-tubules is sufficient for 
contraction (Gilly and Scheuer, 1984). In the skeletal muscles of vertebrates and muscles 
of some invertebrates, mostly molluscs and arthropods, the influx of calcium via cell 
membrane VGCC is coupled to the activation of RyR channels and release of calcium from 
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the SR (Loesser et aI., 1992; Marx et aI., 1998; Bers & Fill, 1998). This functional coupling is 
possible because of structures called "junctional feet", tetrameric arrays of RyRs 
connecting the gap between the T tubule and SR, where every other RyR is associated 
with a VGCC on the T tubule (Bers and Fill, 1998). However, the presence of junctional feet 
in Drosophila larval muscles is yet to be shown. 
1. 7 Objectives 
In recent years, Drosophila has become a model of choice when investigating the 
modulatory effects of neuropeptides, for several reasons. First, all the motor neurons and 
muscle fibres in the larval body wall have been identified, making it possible to study 
synaptic interactions between known cell pairs. Secondly, the whole genome is 
sequenced and, with the continuous development of molecular and genetic techniques, 
an enormous number of genetic mutants and transgenic fly lines have become readily 
available to use for dissecting molecular particulates underlying physiological functions. 
With the development of UAS-GAL4 system, researchers are able to downregulate or 
upregulate the expression of specific genes in a temporal and tissue-specific manner. 
Using Drosophila as a model system, the following three questions are addressed in 
this thesis (Fig lB) : 
1. Is the ability of DPKQDFMRFamide to induce muscle contraction mediated via a 
GPCR? 
2. Which secondary messenger systems are involved in mediating the peptide's 
action on muscle? 
3. Are the effects of DPKQDFMRFamide truly postsynaptic effects? 
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As described above, RFamides can act via two types of receptors, ligand-gated Na+ 
ion channels and GPCRs. Four RFamide GPCRs were cloned and characterized in 
Drosophila melanogaster, but only one, FR (gene:CG2114), was found to be highly 
sensitive to dFMRFamide-containing peptides and less to other -RFamide peptides 
(Meeusen et aI., 2002; Cazzamali & Grimmelikhuijzen, 2002). To demonstrate that 
DPKQDFMRFamide is acting via FR to elicit contractions in Drosophila larvae muscle, the 
expression of the FR gene (CG2114) was silenced using the UAS-GAL4 system. If the 
peptide acts via the FR, larvae in which the silencing of the FR gene was driven 
specifically in muscle tissue or ubiquitously should not respond to the peptide. Ifthis 
peptide effect is exclusively postsynaptic, larvae in which the FR gene was silenced only 
in neurons should still respond to the peptide. 
The evidence reviewed in the preceding sections indicates that several 
intracellular messenger signals mediate the effects of -RFamide peptides on muscle 
tissue, including cAMP and IP3. A combination of pharmacologicat biochemical and 
genetic approaches were used in the present study to investigate the possible 
involvement ofthese second messengers in mediating DPKQDFMRFamide's excitatory 
effects on the larval body wall muscle tissue. It was predicted that chemicals which 
inhibit the production or activation of cAMP and cGMP or its effects on kinase enzymes 
would abolish the peptide's effect if those second messengers were involved in 
mediating the peptide's effect. The functional role of cAMP and cGMP in mediating the 
peptide's effect was also confirmed by measuring their levels using an enzyme-linked 
immunosorbant assay. To establish if PLC- IP3 secondary messenger pathway has a role 
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in mediating the peptide's effect, the effect ofthe peptide on muscle contraction were 
tested on larvae of several mutant and transgenic flies with disruptions in activity of 
proteins involved in PLC- IP3 pathway. 
Finally, although the CNS is removed, the motor neurons remained attached to 
the muscles when recording contractions from the whole body wall larval muscles. 
These motor neurons contain a number of different neurotransmitters, the most 
prominent one is glutamate, and the others, such as pituitary adenylate-cyclase 
activating polypeptide, octopamine, proctolin and insulin-like peptide (Peron et aI., 
2009, Budnik & Gramates 1999). Previously published evidence (Clark et aI., 2008) 
showed that desensitizing glutamate receptors, and hence preventing the activation of 
glutamate receptors by glutamate released from presynaptic terminals, does not affect 
the ability of the peptide to induce contractions and increase muscle tension in 
Drosophila larval body wall muscles. This provides evidence that the peptide is not 
acting presynaptically to release glutamate, but it does not exclude the possibility that 
any of the other neurotransmitters are being released and further acting on larval 
muscle themselves. To give an answer to this question, I compared transduction 
pathways known to mediate the presynaptic effects to those that are mediating 
postsynaptic effects. The prediction was that if the peptide-induced increase in 
neurotransmitter release is responsible for the peptide's myogenic effects, then 
inhibiting the molecular mechanisms known to mediate the presynaptic effects would 
also abolish the peptide's effect on muscle contraction. 
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Figure 1. Model of DPKQDFMRFamde's action on body wall muscle contractions of 
Drosophila melanogaster. A) DPKQDFMRFamide induces phasic contractions and 
increases body wall muscle tonus (Clark et aI., 2008). This effect depends on the 
activation of voltage gated calcium channels (VGCC). B) DPKQDFMRFAmide exerts its 
myotropic effects, presumably, by activating a muscle membrane receptor. This study 
aims to examine if the peptide acts through a GPCR encoded on the Drosophila FR gene 
(CG2114) and whether it requires activation of second messengers, more specifically, it 
examines the involvement of cAMP, cGMP, IP3 and CaMKl1. 
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2. METHODS 
2.1 Fly stocks 
Canton S (CS) flies, obtained from Bloomington Drosophila Stock Centre (BOSC) 
were used for the experiments unless otherwise indicated. 
The IP3 receptor mutant used was Itp_r83AoS616 {P{PZ}ltp_r83AoS616 Nmdar1oS616 
rlo6/TM3, rlKSb1Ser1} (BOSC, donated by Berkeley Drosophila Genome Project). This 
mutation had been generated by inserting a single transposable element in the 3rd 
chromosome to disrupt the IP3 receptor encoding gene, itp-r83A (Spradling et aI., 1999). 
Since this mutation was balanced over a Sb1Ser1 dominantly marked balancer 
chromosome, a genetic cross scheme was designed to remove this balancer. First, a 
cross between the IP3 mutant receptor line and the w*; Sb1/TM3, P{ActGFP}JMR2, Ser1 
balancer line (BOSC) was constructed to obtain progeny with the P element insertion 
balanced over TM3, P{ActGFP}JMR2, Ser1. Then, the selected progenv line was further 
crossed with w 1118 flies (BOSC) to remove the GFP, Ser1 marked balancer chromosome 
(Fig.2). 
Four different flV lines with mutations in two genes encoding for PLCP were used. 
These included three mutants of the norpA (no receptor potential) gene, which were: w* 
norpA33, w*norpA36 and norpA7 (BOSC). OregonR was the wild tvpe strain used as a 
control for norpA gene mutants. In addition, the Plc21C gene mutation line (/W1118; 
PBac{SHPw+}PIc21CA246 ) was used with its corresponding control line (V, w), both of 
which were acquired from BOSe. 
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Fig.2. Schematic diagram of the genetic cross used to remove the balancer chromosome 
from the IP3 receptor mutants and to obtain 3rd-instar larvae heterozygous for the IP3 
receptor mutation (w; P{PZ}ltp_r83A05616 Nmdarl05616 rl06/ +) that could be further 
tested in the muscle contraction assay. Male and virgin female flies heterozygous for the 
P element insertion (P{PZ}ltp_r83A05616) and the Sb, Ser marked balancer were cros~ed to 
either virgin females or males heterozygous for Sb and the green fluorescent protein 
(GFP), Ser marked balancer, respectively. From the progeny of this cross, only 3rd instar 
larvae expressing GFP were individually isolated and allowed to reach the adult stage. 
From these, only male and virgin female adult flies with normal bristles (non Sb 
expressing) were selected (w; P{PZ}ltp_r83Ao5616 Nmdarl05616 rl06/ TM3, 
P{ActGFP}JMR2, Ser1) for the next cross. Finally, to remove the GFP, Ser marked 
balancer chromosome, male or virgin female flies from Fl were crossed with flies of the 
opposite sex, carrying wild type 3rd chromosome and w 1118 mutation on the X 
chromosome. 3rd-instar larvae ofthe F2 progeny lacking GFP expression (w; P{PZ}ltp-
r83A05616 Nmdarl05616 ryS06/ +) and the control line (w 1118) were assayed for 
DPKQDFMRFamide-induced muscle contractions. ry, rosy; Sb, Stubble; Ser, Serrate. 
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To investigate the role of CaMKIl an ala 1 {w P[w+ ala]} transgenic line was used. 
This line had been constructed by inserting a synthetically generated alanine inhibitory 
peptide gene on the first chromosome under the control of a heat shock promoter 
(Griffith et ai, 1993). The gene for the synthetic alanine inhibitory peptide was 
constructed based on the sequences of the rat a CaM kinase autoregulatory domain 
(Griffith et aL, 1993). The UAS-ala line contains an alanine inhibitory peptide gene 
inserted downstream of UAS and was used as a control for ala1line. Both transgenic 
lines were generous gifts from Dr Leslie Grifith (Brandeis University, Mass). 
A transgenic line containing FMRFamide receptor inverted repeat (FR-IR ) 
downstream from the upstream activating sequence (UAS) was obtained from the 
Vienna Drosophila RNAi Center (VORC #9594}.The generation of this line (UAS-FR RNAi) 
was described by Oietzl et aL (2007). Briefly, a FMRFamide receptor gene fragment was 
cloned as a 301bp long inverted repeat (IR) in antisense-sense orientation into a 
modified pUAST vector, pMF3 with multiple UAS sites. This cloned construct was then 
inserted on the second chromosome of an isogenic W l1i8 host, generating a homozygous 
viable UAS-FR RNAi line. 
The following driver lines were used to express the RNAi for the FR: elav-GAL4 
(BOSC) and 24B-GAL4 (BOSC) and tubP-GAL4 (BOSC). elav-GAL4 is a homozygous and 
viable transgenic line with the P{GAL4-elav.L} construct inserted at the third 
chromosome. The neuron-specific promoter from the gene elav drives the expression in 
all postmitotic neurons starting at stage 12 of embryonic development (Luo et ai, 1994, 
Sink et aL, 2001). In this study, elav-GAL4 was used for pan-neuronal expression of the 
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UAS-FR-IR transgene. 24B-GAL4 is a homozygous enchancer trap line that expresses 
GAL4 in mesoderm as early as stage 11 of embryonic development (Luo et aI., 1994, 
Brand and Perrimon, 1993) and in all larval somatic muscles (Schuster et al.,1996). tubP-
GAL4 is an insert on the third chromosome that is balanced over TM3, Sb and allows for 
ubiquitous expression of Gal4 (Lee and Luo, 1999). 
All flies were raised on a cornmeal-based medium (Boreal Laboratories Ltd., St. 
Catharines, Ontario, Canada), supplemented with dry yeast, at 21°C on a 12:12 light-
dark cycle. 
2.2 Genetics 
Tissue-specific expression of the UAS-FR IR construct was driven using the UAS/GAL4 
system as described by Brand and Perrimon (1993). To express the UAS-FR IR construct 
ubiquitously, homozygous UAS-FR RNAi virgin females were crossed to tubP-GAL4 males 
that were previously balanced over TM3, P{ActGFP}JMR2, Ser1 (Fig 3A). In addition, 
tubP-GAL4 males balanced over TM3, P{ActGFP}JMR2, Ser1 were crossed with W ll18 
virgin females to remove the balancer chromosome and generate a heterozygous 
control line (Fig 3B).Expression of the UAS-FR IR construct in muscle and neuronal 
tissues was accomplished by crossing homozygous UAS-FR RNAi virgin females to 
homozygous 24B-GAL4 and elav-GAL4males, respectively. Heterozygous larvae of the F1 
generation were used for the experiments (Fig. 4A, SA). To generate appropriate 
heterozygous Gal4 controls, homozygous elav-GAL4 and 24B-GAL4 males were crossed 
to W l118 virgin female flies (Fig. 4B, SB). To generate appropriate control larvae with 
non-activated UAS-FR construct, homozygous UAS-FR RNAi virgin females were mated 
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Fig. 3. Schematic diagram representing crosses designed to generate larvae with 
ubiquitous knockdown/reduction of FR expression (A) and their respective Gal4 control 
line (B). First, to be able to differentiate between 3rd instar larvae of different genotypes, 
I took advantage of a GFP marked balancer. larvae carrying the GFP marked balancer 
express GFP markedly in the salivary duct, the copper cells, the proventriculus and the 
visceral musculature of the midgut (Reichhart and Ferrandon, 1998) and are easily 
recognizable under a fluorescent dissecting microscope. Hence, I replaced the Sb 
marked balancer with the GFP, Ser marked balancer. This was accomplished by crossing 
male flies heterozygous for Sb and the green fluorescent protein (GFP), Ser marked 
balancer (Wll18 ; + ; Sb1/TM3, P{ActGFP}JMR2, Serl )with virgin females carrying one copy 
of the tubP-Gal4 insert balanced over the Sb marked balancer (W1ll8 ; +; tubP-GaI4/ TM3, 
Sb1) (A,B). From the progeny of this cross (F1), only 3rd instar larvae expressing GFP were 
individually isolated and allowed to reach the adult stage (A,B) . From these, only male 
and virgin female adult flies with normal bristles (non Sb expressing) were selected to 
obtain flies with W 1ll8; tubP-GaI4/TM3, P{ActGFP}JMR2, Serl ; + genotype for the next 
cross. Next, male flies selected from the F1 generation (Wll18 ; tubP-GaI4/TM3, 
P{ActGFP}JMR2, Serl ; + ) were crossed with either A) virgin females homozygous for the 
UAS-FR inverted repeat construct on the second chromosome (W1ll8; UAS-FR RNAi ;+) to 
obtain progeny (F2) expressing a single copy of the UAS-FR inverted repeat construct 
under the control of a single copy oftubP-Gal4 (Wll18; UAS-FR RNAi/+ ; tubP-GaI4/+) or 
B) with wild type virgin females (Wll18; + ;+) to generate larval progeny (F2) with one 
copy of the tubP-Gal4 insert on the third chromosome (Wll18 ; tubP-GaI4/+) . ry, rosy; Sb, 
Stubble; Ser, Serrate. 
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FigA. Schematic diagram representing crosses designed to generate larvae with a 
muscle-specific knockdown/reduced expression of FR (A) and an appropriate Gal4 -
control line (B). A) Virgin females homozygous for the UAS-FR inverted repeat construct 
on the second chromosome (Wll18 ; UAS-FR RNAi ; +) were crossed with males 
homozygous for the 24B-Ga14 insert on the third chromosome (Wll18 ; +; 24B-GaI4) to 
obtain progeny (Fl) expressing a single copy of the UAS-FR inverted repeat construct 
under the control of a single copy of 24B-Ga14 (Will8 ; UAS-FR RNAi /+ ; 24B-GaI4/+). B) 
In parallel, males homozygous for the 24B-Ga14 insert on the third chromosome (Will8 ; 
+; 24B-GaI4) were crossed with wild type virgin females (Will8; + ;+) to generate larval 
progeny with one copy of the 24B-Ga14 insert on the third chromosome (Wll18 ; +; 24B-
GaI4/+). 
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Fig. 5. Schematic diagram representing crosses designed to generate larvae with a 
neuron specific knockdown/reduced expression of FR (A) and an appropriate Ga14 -
control line (B). A) Virgin females homozygous for the UAS-FR inverted repeat construct 
on the second chromosome (W1118 ; UAS-FR RNAi ; +)were crossed with males 
homozygous for the elav-Gal4 insert on the third chromosome (W1118 ; +; elav-GaI4) to 
obtain the progeny (Fl) expressing of a single copy of the UAS-FR inverted repeat 
construct under the control of a single copy of elav-Gal4 (Wl118 ; UAS-FR RNAi/+ ; elav-
GaI4/+). B) In parallel, males homozygous for the elav-Gal4 insert on the third 
chromosome (W1118 ; +; elav-GaI4) were crossed with wild type virgin females (Wl118; + ;+) 
to generate larval progeny with one copy of the elav-Gal4 insert on the third 
chromosome (Wl118; +; elav-GaI4/+). 
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Fig.G. Schematic diagram of the cross designed to generate a control fly line with non-
activated UAS-FR inverted repeat construct expression (Wl1l8; UAS-FR RNAi/+). Virgin 
female flies homozygous for the UAS-FR construct (Wll18; UAS-FR RNAi; +) were crossed 
with male wild type flies (Wll18; + ;+) to generate a fly line heterozygous for the UAS-FR 
construct on the second chromosome. The Fl generation 3rd instar larvae were tested in 
the muscle contraction assay. 
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to W ill8 virgin female flies (Fig 6). All crosses were kept at 2rC on a 12:12 light-dark 
cycle. 
2.3 Preparation 
Wandering stage third-instar larvae were used for all experiments. They were 
collected from the sides of their culture vials immediately before dissections were made. 
All dissections were made at room temperature ("'21 DC) in modified hemolymph-like 
(HL6) Drosophila physiological saline (Macleod et ai, 2002). The saline contained (in 
mM): 23.7 NaCl, 24.8 KCI, 0.5 CaCI2, 15 MgCI2, 10 NaHC03, 80 trehalose, 20 Isethionic 
acid, 5.7 L-alanine, 2.0 L-arginine, 14.5 glycine; 11.0 L-histidine; 1.7 Lmethionine; 13.0 L-
proline; 2.3 L-serine; 2.5 L-threonine; 1.4 L-tyrosine; 1.0 L-valine and 5 BES, pH 7.2. The 
saline was stored at -20 DC in 200 mL aliquots. 
The larvae, oriented dorsal side up, were pinned down at the anterior and 
posterior ends to a Sylgard (Dow Corning Corporation, Midland, ML) dish containing 
saline. The larvae were stretched slightly longitudinally, and a mid-dorsal cut was made 
along the length of the animal (Fig 7, top). The entrails were removed, and the 
segmental nerves were cut near the ventral ganglion, which was subsequently removed 
along with the brain, as previously described by Jan and Jan (1976). Subsequently, the 
preparations were used for either the muscle contraction recording or enzyme 
immunoassay. 
2.4 Muscle contraction recordings 
After the dissection, the pin in the anterior end of the larva was removed and 
simultaneously the anterior tip of the larva was hooked to a Grass FT03 tension 
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used to record body wall muscle contractions. 
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transducer (Grass Instruments, Quincy, MA) as previously described (Clark et al,,2008). 
Briefly, an L-shape bent insect pin was glued to a 54 mm metal rod which was attached 
to the force transducer at an angle that was perpendicular to the spring. The bent insect 
pin was hooked to the anterior end of the animal in such a way that contractions of the 
longitudinal muscles were parallel to the movement of the force transducer's spring. 
The larval body wall muscles were stretched slightly longitudinally by pulling the body in 
a dorsal and anterior direction until the larva was situated at an angle approximately 45 
o from horizontal (Fig 7, bottom). Contractions were amplified using a MOD CP 122A 
amplifier (Grass Telefactor, W. Warwick, RI) and were recorded on an Omniscribe chart 
recorder (Austin, Texas, USA). Calibration was performed using a pin of known mass and 
the following conversion, 1 mg= 0.009807 mN. 
The recording dish had a volume of approximately 0.2-0.4 ml and was 
continuously perfused at a rate of 0.7 ml/min. As in previous experiments (Clark et ai, 
2008), applications of DPKQDFMRFamide caused irregular, rapid contractions, 
superimposed on a slow contraction lasting several minutes. Because the fast 
contractions were highly variable in occurrence and magnitude, the effect of the peptide 
was quantified (as in Clark et ai, 2008) as the magnitude of the slow contractions, which 
corresponded to an increase in muscle tonus. To investigate the effect of peptide on 
muscle tonus in third instar larvae from the F1 generation of the various crosses, the 
peptide was applied for 5 min, and the maximal tonus was compared to the tonus 
during a 5-min pre-peptide period (basal tonus) to obtain the change in tonus. The 
peptide was washed out with saline for approximately 15 min, after which 300mM KCI 
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was applied for 5 min to ensure that the preparation was able to contract. The results 
are reported as means ± standard errors of mean (SEM). 
The effects of DPKQDFMRFamide and different pharmacological agents were 
examined by exchanging experimental solutions. Excess fluid was removed by 
continuous suction. To investigate the effects of different pharmacological agents on 
the DPKQDFMRFamide-induced tonus change, the following procedure was followed. 
The peptide was applied for 5 min and washed out for approximately 15 min, which was 
followed by 10 min (20 min for KN-93) of perfusion with saline containing the chemical 
of interest and then 5 min of perfusion with saline containing the chemical and peptide. 
Experimental 
Time (min) 0 5 10 25 35 40 
~ ~ ~ 1 ~ 
peptide I saline pharmacological peptide I saline 
agent + 
pharmacological 
agent 
Control 
Time (min) 0 5 10 25 35 40 
~ l ~ ~ l 
I peptide I ~ I saline ~ 
Fig 8. Schematic diagram demonstrating the time line and the order of solution 
applications during the muscle contraction recordings. 
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In the control trials the same perfusion procedure was followed, but the 
pharmacological agents were omitted from the solutions (Fig. 8). When DMSO was used 
to dissolve the chemical of interest, the DMSO concentration was consistent throughout 
each trial, and it was matched in control trials. To establish the effects of applied 
chemicals, the maximum tonus change during the 5 min peptide + chemical application 
period in the experimental trials was compared to the maximum tonus change within 
the second 5 min peptide application period in the control trials. 
2.5 Heat-shock 
Ala 1 and UAS-ala flies were placed in empty glass vials and placed in a dry 
incubator for 1 hour at 37°C. After the heat-shock, flies were allowed to recover at 
room temperature (21°C) for approximately two hours before muscle contractions were 
recorded .. 
2.6 cAMP and cGMP enzyme immunoassays. 
Dissected preparations of larval body wall muscles were placed in a Petri dish 
containing cold saline from which pools of 2-9 larval preparations were transferred into 
100 III of desired incubation solution. Individual pools of tissues to be tested for cAMP 
content were incubated separately in either (a) saline, (b) a non-selective 
phosphodiesterase inhibitor 5 x 10-4 M 1 3-isobutyl-l-methylxanthine (lBMX), (c) 5 x 10-4 
M IBMX containing either DPKQDFMRFamide at concentrations ranging from 10-8 to 10-6 
M or 5 x 10-5 forskolin (an adenylate cyclase activator) (d) 5 x 10-4 M IBMX containing 5 x 
10-5 forskolin or (e) 5 x 10-5 M forskolin alone. Preparations to be assayed for cGMP 
were incubated in either (a) saline alone, (b) saline containing 5 x 10-4 M IBMX or (c) 
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saline containing 5 x 10-4 M IBMX with concentrations of DPKQDFMRFamide ranging 
from 10-8 to 10-6 M. All incubation solutions contained 0.25 % DMSO with the exception 
of solutions containing forskolin, which had 0.65% as the final DMSO concentration. 
After 10 minutes of incubation at room temperature, each larval pool was placed into 
100 III of 0.1 M hydrochloric acid (HCI) for 5 min to inhibit endogenous 
phosphodiesterase activity. To halt the chemical reactions, the larvae were placed onto 
a steel plate cooled over dry ice, which resulted in immediate tissue freezing. Frozen 
tissue was homogenized in 500 III of 0.1 M HCI and then centrifuged for 12 min at 
11,000 x g. The supernatant was transferred into fresh 1.5 ml Eppendorf tubes and 
stored at -80 °C until ready to assay for cAMP or cGMP content. The pellet was further 
submitted to a protein determination assay. 
Levels of cAMP or cGMP were determined in duplicates from supernatant (100 
Ill) following the acetylated protocol for a direct cAMP enzyme immunoassay kit or 
overnight acetylated version of a direct cGMP enzyme immunoassay kit (Assay Designs, 
Ann Arbor, USA). Standards and supernatants were acetylated by adding 10 III of 
acetylating reagent for each 200 III of supernatant or standard. The acetylating reagent 
was prepared as a 2:1 mixture of triethylamine (99.5%) and acetic anhydride (98%) 
supplied in the kit. The sample and standard wells were prepared by adding neutralizing 
agent, cAMP (or cGMP) conjugate and a rabbit polyclonal antibody to cAMP (cGMP) into 
wells coated with goat antibody specific to rabbit IgG. Supernatant or standards were 
added to the wells, and each plate tested contained a set of blank controls and non-
specific binding controls. The cAMP plates were incubated on a plate shaker (300rpm) at 
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room temperature for 2 hours. cGMP plates were incubated overnight at 4° C. After 
the appropriate incubation period, plates were washed a total of 3 times with a wash 
buffer using a Bio-Tek EL x 50™ automated strip washer (BioTek, Vermont, USA). After 
the final wash, a p-nitrophenyl phoshate buffer solution was added to each well, after 
which the plates were incubated for one hour at room temperature. The reaction was 
stopped by adding 50 III of a trisodium phosphate solution (1O%) to each well. The 
optical densities were read at 405 nm with a Bio-Tek SynergyTM HT microplate reader 
(BioTek, Vermont, USA), and the concentrations of cAMP (pmol/ml) or cGMP ( pmol/ml) 
were estimated using a 4 parameter logistic curve-fitting program provided in the Bio-
Tek KC4™ Software. The sensitivities of the acetylated version of the cAMP and cGMP 
assays were 0.037 pmol/ml and 25 pmol/ml, respectively. 
Each pellet was dissolved in 100111 of 1M NaOH and placed for 2 hours in a hot 
water bath (40°C). Protein content was measured from 10-15 III of solubilized pellet 
with a BioRad Protein Assay kit (based on method of Bradford, 1976) using bovine serum 
albumin as a protein standard. Absorbances were read at 595 nm using a spectronic 20 
(Bausch and Lomb incorporated, USA). 
To account for variations in the number and sizes of larval body wall 
preparations, the final results are expressed as pmol per mg of protein. 
2.7 Chemicals and Peptide 
The Drosophila peptide, DPKQDFMRFamide, was synthesized by Cell Essentials 
(Boston, Mass.) and was 98% pure as determined by reverse-phase High Performance 
Liquid Chromatography (HPLC). Peptide was stored at -20 ·C and was dissolved in saline 
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to yield a 10 mM stock solution. 3-lsobutyl-l-methylxanthine (IBMX) was purchased 
from Sigma-Aldrich (Oakville, ON., Canada). 5 mM IBMX stock solution was made in 0.5 
% DMSO containing saline and kept at -20°C. The DMSO concentration in the final IBMX 
solution used for physiological recordings did not exceed 0.05%. Forskolin, adenosine 
3',s'-cyclic monophosphorothioate, Rp-Isomer, triethylammonium salt (Rp-cAMPS), 
guanosine 3',s'-cyclic monophosphorothioate, 8-(4-Chlorophenylthio}-, Rp-Isomer, 
triethylammonium salt (Rp-8-pCPT-cGMPS) and KN-93 were obtained from Calbiochem. 
Forskolin and KN-93 were dissolved in 100 % DMSO and stored at 4 °C as stock solutions 
(12 and 10 mM, respectively), which were subsequently diluted in saline to yield the 
desired drug concentration with final DMSO concentrations of 0.4 % and 0.1 %, 
respectively. 5 IlmOI of Rp-cAMPS and 11lmol of Rp-8-pCPT-cGMPS were stored at -20 
°C until ready to dilute in saline to yield the desired final concentration. All experimental 
solutions were made fresh on the day of testing. 
2.8 Analysis 
Both one way ANOVA and t-test for independent samples, unless otherwise 
stated, were used where appropriate to determine statistical significance, and p<O.Os 
was used for acceptance of statistical significance. All data were expressed as means ± 
standard error of the mean (SEM). The number of preparations is indicated in the 
parentheses on the graphs (n). 
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3. RESULTS 
3.1 FMRFamide G-protein coupled receptor (FR) mediates the stimulatory effect of 
DPKQDFMRFamide on Drosophila larval body wall muscles 
To investigate whether the GPCR encoded by the Drosophila FR gene (CG-2114) 
plays a role in mediating the effects of DPKQDFMRFamide on muscle tonus, a 
combination of genetic tools known to induce tissue-specific silencing of gene 
expression was used to alter the function of this gene in Drosophila larvae. One of the 
most prominent mechanisms used for gene silencing is RNA interference (RNAi). In this 
post transcriptional gene silencing system, a double-stranded RNA targets other 
homologous RNAs which are subsequently destroyed by the RNA-induced silencing 
complex (RISC), resulting in the reduction of the targeted gene expression. Several 
genetic methods have been developed to introduce double-stranded RNAs into different 
organisms, including the transfection of Drosophila cells with an inverted repeat (IR) 
transgene construct (Ashburner et aI., 2005). An IR transgene construct contains a gene 
sequence that is complementary to a portion of the target gene and is transcribed into a 
hairpin RNA (one-stranded RNA folded on itself) that is able to target the transcripts of 
the same target gene. Transcription of an inverted repeat (IR) transgene construct under 
the control of UAS/GAL4 system (Brand and Perrimon, 1993) has been successfully used 
to induce tissue-specific posttranscriptional Silencing of gene expression in Drosophila 
(Fortier and Belote, 2000, Kennerdell and Carthew, 2000, Martinek and Young, 2000, 
Lam and Thummel, 2000, Piccin et aI., 2001). 
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To reduce expression of the FR gene transcript in all larval tissues, homozygous 
transgenic flies carrying the FR inverted repeat under the control of UAS (UAS-FR RNAi) 
were crossed with flies that exhibit ubiquitous expression of GAL4 homozygously under 
the control of the tubulin promoter (tubPGAL4). The change in muscle tonus in 
response to 111M DPKQDFMRFamide was significantly attenuated in the larval progeny 
ofthis cross (UAS-FR RNAi/+; tubP-GAL4/+; Fig 9D). In these progeny, peptide treatment 
increased muscle tonus by only 9.86 ± 3.45 IlN, which was approximately 30% of the 
response elicited in larvae from both parental control lines (tubP-GAL4/+ genotype and 
UAS-FR RNAi/+ genotype; Fig. 91; one-way ANOVA, Tamhane's post hoc, p<O.Ol). The 
response in the progeny (ie. UAS-FR RNAi/+ ; tubP-GaI4/+) was only 26% ofthe Canton-S 
response (Fig. 91; one-way AN OVA, Tamhane's post hoc, p<0.05). No difference was 
observed between the DPKQDFMRFamide-induced contractions of the two parental 
control lines (Fig. 91; Tamhane's post hoc, p>0.05), nor between the parental control 
lines and Canton-S larvae (Tamhane's post hoc, p>0.05), in which expression ofthe FR 
gene was not manipulated. Thus, combining the UAS-FR RNAi line with GAL4 to 
ubiquitously disrupt the functionality of FR was successful at inhibiting the peptide's 
ability to elicit contraction. These results suggest that the FR is at least partially 
responsible for mediating the myostimulatory effect of peptide on larval body wall 
muscles. 
The 24B-Ga14 driver (P{GawB}how24B}) expresses Gal4 in all embryonic and larval 
somatic muscles under the control of regulatory sequences from the held out wings 
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Fig. 9. DPKQDFMRFamide modulates larval muscle tonus via the FMRFamide G-protein 
coupled receptor (FR). Sample recordings in A and B demonstrate tonic larval body wall 
muscle contractions in response to application of 1 ~M DPKQDFMRFamide (arrows) of 
two control lines, Canton S and a line containing a single copy of non-activated FR IR 
construct (UAS-FR RNAi/+), respectively. Trace recordings of peptide-induced muscle 
contractions from larvae expressing only a single copy of the ubiquitous (tubP-GaI4/+), 
muscle specific (24B-GaI4/+) or neuron-specific (elav-GaI4/+) Gal4 driver but do not 
express a UAS-FR IR construct were presented in C, E and G traces, respectively. Traces 
D, F, and H represent muscle contraction recordings in response to the peptide in larvae 
in which the UAS-GAL4 system was used to drive the expression of a FMRFamide 
receptor inverted repeat (FR IR) in ubiquitous (D), muscle tissue specific (F) and pan-
neuronal patterns (H). Upward deflections represent phasic contractions. B} Summary 
of responses to 1 ~M DPKQDFMRFamide in each line. The response was attenuated in 
larvae with the ubiquitous expression of FR IR construct, UAS-FR RNAi /+; tubP-GAL4/+ 
larvae, but not in heterozygous parental control lines, UAS-FR RNAi/+ and tubP-GAL4/+ 
larvae (Tamhane's post hoc, p<O.Ol). Similarly, larvae expressing the FR IR construct 
specifically in muscle tissue (UAS-FR RNAi/+; 24B-GAL4/+) showed a reduced response to 
the peptide (by ..... 85-90%) when compared to two heterozygous parental control lines, 
UAS-FR RNAi/+ and 24B- GAL4/+ larvae (Tamhane's post hoc, p<O.Ol). Pan-neuronal 
expression of the FR IR construct in Drosophila larvae had no effect on the peptide's 
ability to modulate muscle tonus. No differences were found between the response of 
UAS-FR RNAi/+; elav-GAL4/+ larvae and their parental controls (UAS-FR RNAi/+ and elav-
GAL4/+ larvae, One-Way ANOVA, Tamhane's post hoc, p>O.OS). A triangle indicates 
significance of p<O.OS compared to Canton-S flies. A square represents a significant 
difference (p<O.OS) compared to UAS-IR-FR line. 
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gene (how) (Schuster et aI., 1996). To express the FR-IR construct specifically in muscle 
cells, and hence disrupt the function of the receptor specifically in muscle tissue, the 
UAS-FR-RNAi flies were crossed with 24B-GAL4 flies to yield a heterozygous F1 
generation (UAS-FR RNAi/+; 24B-GAL4/+). To control for potential effects of P-vector 
insertions present in all larvae, two control lines were used, heterozygous UAS-FR RNAi 
flies with a non-active UAS-FR IR construct and heterozygous 24B-GAL4 lines containing 
a Gal4 vector only. The change in the body wall muscle tonus of the larvae with RNAi-
regulated expression of FR gene (UAS-FR RNAi/+; 24B-GAL4/+) in response to the 
peptide is shown in Fig. 9F. Expression ofthe FR RNAi in muscle cells reduced the 
amplitude of the muscle tonus elicited by the peptide to 11% and 15% of the responses 
in UAS-FR RNA and 24B-GAL4 controls, respectively (Fig. 91, Tamhane's post hoc, p<0.05 
and p<O.Ol), and to 9% of those recorded from Canton-S larvae (Fig 91, Tamhane's post 
hoc, p<0.05). There was no difference between the peptide-induced body wall 
contraction of Canton-S, UAS-FR RNA and 24-GAL4 control larvae (Tamhane's post hoc, 
p>0.05) in which expression ofthe FR gene was assumed to be normal. This suggests 
that the presence of the FR on the postsynaptic muscle cell is necessary for most if not 
all of the peptide-induced contraction. This result also corroborates previously reported 
evidence that the effect of DPKQDFMRFamide on tonus of larval body wall muscles is 
due to a postsynaptic action (Clark et aI., 2008). 
To examine the possibility that the tonus change is mediated by presynaptic 
actions of the peptide, neuron-specific expression of the FR inverted repeat was induced 
by crossing UAS-FR RNAi flies with flies harbouring pan-neuronal GAL4 expression under 
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the control of a single copy of the elav-Gal4 driver. The responses of UAS-FR RNAi /+; 
elav-GAL4/+ and two control progeny lines, heterozygous UAS-FR RNAi and 
heterozygous elav-GAL4larvae, to l~M DPKQDFMRFamide application are shown in Fig 
9H, B, G, respectively. DPKQDFMRFamide increased muscle tonus by 35.61 ± 4.18 ~N in 
larvae with pan-neuronal expression of FR IR, which was similar to the change in tonus 
observed in heterozygous control elav-GAL4 (Fig. 91; 43.02 ± 8.62 ~N, Tamhane's post 
hoc, p>0.05) and UAS-FR-IR larvae (Fig. 91; 31.96 ± 5.83 ~N, Tamhane's post hoc, p>0.05) 
as well as to the response of Canton-S larvae (Fig. 91; 38.11 ± 4.92 ~N, Tamhane's post 
hoc, p>0.05). Pan-neuronal expression ofthe FR IR construct had no effect on the ability 
of peptide to increase muscle tonus. 
3.2 PLC-IP3 pathway 
The results presented above suggest that the effect of DPKQDFMRFamide on 
body wall muscle tonus is mediated via a GPCR. Binding of a signal molecule to a GPCR 
results in activation of a G-protein that subsequently modulates the activity of various 
enzymes, ion channels or transport proteins and usually leads to a change in the 
production of second messengers. One of the major second messenger molecules that 
plays an important role in signal transduction is inositol trisphosphate (IP3). IP3 is 
produced by hydrolysis of PIP2, which is catalyzed by Phospholipase C (PLC). This 
reaction produces DAG and IP3, both of which act as second messenger molecules. IP3, is 
a small water-soluble molecule whose primary function is release of Ca2+ from 
intracellular stores, primarily endoplasmatic reticulum (ER), in a variety of cells, including 
muscles (Berridge., 1984, Berridge., 2009, Krauss, 2001). Calcium release from internal 
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stores is accomplished by the binding of IP3 to the ligand gated ion channels called IP3 
receptors. 
Excitatory effects of RFamides have been previously associated with increasing 
IP3 levels in heart tissue of Lymnea stagnalis (Willoughby et aLI 1999b) and tentacle 
retractor muscles of Helix aspersa (Falconer et aLI 1993). In addition, the ability of 
FMRFamide and FLRFamide to increase tonus in Lymnea stagnalis heart was inhibited by 
approximately 40 % in the presence of 2.5 mM neomycin, a PLC inhibitor (Willoughby et 
aLI 1999b). These observations make the PLC-IP3 pathway an attractive candidate for 
mediating DPKQDFMRFamide's excitatory effects. If the peptide's effects are indeed 
mediated via the PLC-IP3 pathway, it would be predicted that the ability of the peptide 
to increase muscle contraction would be attenuated or abolished by disrupting either 
PLC or IP3 receptor (IPrR) activity. To investigate this hypothesis, I took advantage of 
Drosophila fly lines in which either PLC or IP3 receptor functionality had been disturbed 
with mutations in genes (norpA and Plc21C) that encode for PLC~ or in the single gene 
known to encode for the IP3 receptor, itpr, respectively. 
Heterozygous IP3 receptor mutant larvae (Itp_r83Ao5616) exhibit approximately 
50% reduction in IP3-R transcript levels (Klose et aLI 2010). Fig. lOA shows the averaged 
change in the body wall muscle contraction of heterozygous IP3 receptor mutants (Itp-
r83Ao5616) and wild type larvae in response to the DPKQDFMRFamide. The mutant larvae 
responded to peptide with an average muscle tonus increase of 27.74 ± 2.87 IlN, which 
was not significantly reduced from the response elicited by peptide in wild type larvae 
(t-test, p> 0.05). 
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Fig. 10. Disruption of PLC~ or IP3 receptor activity had no effect on the ability of 
DPKQDFMRFamide to modulate muscle tonus in Drosophila larvae. Muscle contraction 
assays were performed by perfusing body wall muscles with 111M peptide for 5 minutes 
and recording the tonus change. The tonus change was calculated as the difference 
between the maximal rise in tonus within the 5 minute peptide application period and 
the pre-peptide tonus level. Muscle contraction assays were performed on fly lines 
carrying mutation on the genes encoding for A) IP3 receptor (itpr) or B) PLC~ (norpA or 
plc21C gene). No significant difference was observed between the effect of the peptide 
on muscle tonus in heterozygous IP3 receptor mutants (Itp_r83Ao5616) and wild type 
larvae (t-test for independent samples, p>O.OS). The peptide increased muscle tonus in 
all norpA mutants (w* norpA33, w* norpA36 and norpA7) and P/c21C mutant (l W l118; 
Plc21CA24) larvae to a level comparable to their respective controls, Oregon Rand y,w. (t-
test for independent samples, p>O.OS). 
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Each of the mutants, w* norpA33, w* norpA36 and norpA7 carries a point mutation 
in the norpA gene induced by ethyl methanesulfonate mutagenesis on the Oregon-R 
line. PLC activity is reported to be reduced to approximately 1-1.5 % of wild type levels 
(Pearn et aL, 1996), and PLC activity in norpA7 mutants is reduced to about 2-3% of 
normal levels (Inoue et aL, 1988). The Plc21C gene mutant, l W l118; Plc21CA24, had been 
designed using P element insertion mutagenesis (Bellen et aL, 2004). Although it has 
been reported that the plc21C gene encodes for two transcripts, of which one is 
expressed in the adult head only and the other is expressed in adult head and body 
tissue throughout development (Shortridge et al., 1991), the exact levels of their 
expression in l W 1118; Plc21CA24 mutant line are yet to be determined. 
The application of 1 ~M DPKQDFMRFamide induced an increase in muscle tonus 
of larval body wall muscles of all PLC mutants (Fig lOB). The maximal increases in tonus 
of w* norpA36, w* norpA33 and norpA7 in response to the peptide were 42.94 ± 10.55 ~N, 
32.49 ± 5.41 ~N and 38.95 ± 6.18 ~N, respectively. These changes in muscle tonus were 
not significantly different from the 39.33 ± 6.03 ~N tonus increase observed in wild type, 
Oregon R larvae (one-way ANOVA, p>0.05). Similar results were found with plc21C 
mutant flies. The response to the peptide was not attenuated in the l W l118; Plc21CA24 
mutant line when compared to the y,w control line (Fig lOB, t-test, p> 0.05). Together 
these data indicate that neither PLC nor IP3 are likely to be involved in mediating 
myostimulatory effects of DPKQDFMRFamide. 
3.3 CaMKIl 
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Ca2+ ions are important intracellular signals implicated in regulating a number of 
processes including muscle contraction. The stimulatory effect of DPKQDFMRFamide on 
body wall muscle contractions requires influx of extracellular Ca2+ (Clark et aL, 2008), 
which suggests that an increase in intracellular Ca2+ concentration immediately follows 
the peptide application. Ca2+ effects are commonly mediated by Ca2+ binding proteins, 
such as calmodulin (CaM), a small protein (148 amino acids) consisting of two domains 
able to bind two Ca2+ ions each (Krauss, 2001).The effects of CaM are most often 
mediated by activation of a multifunctional CaM kinase, CaM kinase II, that consists of a 
dodecameric holoenzyme which gets activated when CaM binds to its autoinhibitory 
domain. This results in dissociation of the catalytic domain from the autoinhibitory 
domain and autophosphorylation of a threonine residue downstream from the catalytic 
subunit (Rosenberg et aL, 2005; Hunter & Schulman, 2005). 
Both genetic and pharmacological disruption of CaMKIl activity was used to test 
the possibility that CaMKIl might mediate the peptide-induced increase in muscle 
contraction. Genetic disruption of CaMKIl activity had been accomplished in the alai 
transgenic line that contains a sequence encoding for the autoinhibitory domain of 
CaMKlI, inserted downstream from a heat shock promoter (Griffith et aL, 1993). At 
room temperature, alai flies express a low level ofthis peptide of 1.9-3.9 uM, which 
prominently increases following heat shock treatment at 37 DC (Griffith et aL, 1993). A 
control for alai flies is the UAS-ala line, which contains the CaMKIl inhibitory peptide 
under the control of a UAS promoter rather than a heat shock promoter. The expression 
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Fig. 11. Genetic and pharmacological inhibition of CaMKIl does not affect the peptide's 
action on tonus of larval body wall muscles in Drosophila. Sample recordings 
demonstrate the effects of 1 ~M DPKQDFMRFamide on spontaneous tonic contractions 
of body wall muscles in alai and UAS-ala larvae. A and B represent the response of 
alai and UAS-ala larvae, respectively, without prior heat-shock treatment, while C and 
o demonstrate the response of alai and UAS-ala larvae, respectively, submitted to a 1 
hour heat-shock treatment at 37°C. Peptide was applied at the upward pointing arrows 
by continuous perfusion. E) Averaged responses from alai larvae, and the control, UAS-
ala larvae. Both groups showed similar increases in tonus in response to peptide 
treatment. Exposing larvae to a heat shock treatment (one hour at 37°C) is known to 
induce an increase in expression of CaMKIl inhibitory protein in ala 1 flies, but not in 
UAS-ala flies. The response to the peptide was potentiated in both alai and UAS-ala 
larvae after subjecting them to heat shock. No significant difference was observed 
between the responses in heat-shocked alai and UAS-ala larvae (t-test for independent 
samples, p>O.OS). F) The averaged change in muscle tonus in Canton-S larvae in the 
presence of a CaMKIl inhibitor. 1 ~M KN-93, a CaMKIl inhibitor, had no effect on the 
peptide's ability to increase muscle tonus (t-test for independent samples, p>O.OS). 
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of CaMKIl inhibitory peptide in UAS-ala flies is not activated until a Gal4 driver is 
introduced. 
Fig 11A and 11B show body wall muscle contractions of alai and their respective 
control (UAS-ala) larvae in response to 1 ~M DPKQDFMRFamide application. The non-
heat-shocked alai larvae showed a similar increase in muscle tonus in response to 
peptide to that of the control line (Fig 11E; t-test, p>0.05). Hence, constitutive 
expression of the CaMKIl inhibitory protein in alai larvae had no effect on the 
DPKQDFMRFamide-induced tonus change. Exposing alai flies to an hour-long heat shock 
treatment at 3rc has been reported to increase CaMKIl inhibitory protein expression 
levels and to decrease CaMKIl activity by 70-100% (Griffith et aI., 1993). Heat-shock 
treatment of alai larvae completely inhibits stimulatory effects of DPKQDFMRFamide on 
EJP amplitude (Dunn and Mercier, 2005) of Drosophila muscle fibres innervated by type 
lb motor neuron boutons. In contrast, the DPKQDFMRFamide-induced muscle 
contraction is enhanced in heat-shocked alai larvae by approximately 150% when 
compared to non heat-shocked alai larvae (Fig 11E, t- test, p<0.05). These results 
suggest that CamKIl is not required for the effects of DPKQDFMRFamide on muscle 
tonus to occur. To test the possibility that the augmented response to the peptide in 
heat shocked larvae is due to the disruption of CaMKIl activity, the peptide was also 
tested on heat-shocked control larvae. Heat shock also increased the peptide's effect on 
muscle tonus in these control larvae; the response was increased by approximately 
100% compared to the non heat-shocked controls (t-test, p<0.05).There was no 
significant difference between the responses of heat-shocked alai and heat-shocked 
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UAS-ala larvae (t-test, p>0.05). These results suggest that the enhanced responses to 
the peptide are attributable to the heat shock treatment rather than to the CaMKIl 
inhibition. 
To further investigate a possible role of CaMKIl in modulation of muscle tonus by 
DPKQDFMRFamide, a pharmacological inhibitor of CaMKIl activity was used (Fig. l1F). 
KN-93, a cell permeable CaMKIl inhibitor, was applied to the preparation at a 
concentration of lj..lM for 20 minutes, and immediately thereafter the preparation was 
exposed to a solution containing lj..lM DPKQDFMRFamide and lj..lM KN-93. The 
concentration of KN-93 used in the experiment is above the ICso level of 0.37j..lM as 
reported by Sumi et aL (1991) and was shown to inhibit the peptide's ability to increase 
EJP amplitude (Dunn and Mercier, 2005). There was no significant difference between 
the muscle tonus change elicited by lj..lM DPKQDFMRFamide alone (29.13 ± 9.59 j..lN) or 
in presence of KN-93 (25.84 ± 3.27 j..lN) (t-test, p>0.05). 
3.4 Cyclic AMP and cyclic GMP pathways 
3.4.1 Effect of DPKQDFMRFamide on cyclic AMP and cyclic GMP levels. 
The modulatory effects of neuropeptides on muscle contractions have been 
associated with the ability of cAMP to change the excitability ofthe cell by modulating 
membrane-bound ion channels (Erxleben et aL, 1995; Bishop et aL, 1991,1987). 
Proctolin, for example, is able to enhance muscle contractions by increasing membrane 
resistance through cAMP-mediated closure of non-voltage dependent K+ channels 
(Erxleben et aL, 1995) and by modulating the activity of Ca2+ channels via a cAMP-
dependent pathway (Bishop et aL, 1991,1987). Since the ability of DPKQDFMRFamide to 
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induce body wall muscle contractions requires activation of L-type Ca2+ channels, it is 
plausible that this peptide activates the cAMP pathway which, in turn, results in the 
activation of VGCc. To investigate whether or not cyclic nucleotides are involved in 
mediating the action ofthe peptide on larval body wall muscles, cAMP and cGMP levels 
in body wall muscles were determined with enzyme immunoassay after incubating the 
tissues in various peptide concentrations in the presence of isobutylmethylxanthine 
(IBMX), a phoshodiesterase inhibitor, known to slow the breakdown of both cAMP and 
cGMP (Beavo et aI., 1970, Beavo & Reifsnyder 1990; Goy, 1990). 
Following the exposure of body wall muscles to DPKQDFMRFamide at 
concentrations ranging from 10 nM to 1~M in the presence of 0.5 mM IBMX, cAMP did 
not differ from the control level (33.0 ± 4 pmol of cAMP/mg protein) measured in IBMX 
alone (Fig 12A, One-Way ANOVA, Tamhane's post hoc, p>O.OS). There was also no 
significant difference between cAMP levels following the exposure of larval muscles to 
0.5 mM IBMX alone and saline alone (Fig 12A, one-way AN OVA, Tamhane's post hoc, 
p>O.OS), which raised a concern that this concentration of a non-specific 
phoshodiesterase inhibitor, IBMX, is not sufficient to increase cAMP levels in Drosophila 
larval muscles. To confirm that the IBMX concentration was sufficient to slow the 
breakdown of cAMP, forskolin, an adenylate cyclase activator, was added in the 
presence and absence of 0.5 mM IBMX. When compared to saline levels, treatment 
with 0.05 mM forskolin alone increased cAMP levels by approximately 230% (Fig 12B, 
one-way ANOVA, Tamhane's post hoc, p<0.01). In the presence of 0.5 mM IBMX, 
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Fig. 12. DPKQDFMRFamide does not affect cAMP levels in Drosophila body wall muscles. 
A) The effects of DPKQDFMRFamide on cAMP levels in larval body wall muscles in the 
presence of 0.5 mM IBMX. cAMP levels following a 10 min incubation of Drosophila 
body wall muscles in 10 nM, 100 nM and 111M DPKQDFMRFamide in the presence of 0.5 
mM IBMX did not exceed the cAMP level observed after incubation in 0.5 mM IBMX 
alone. B) 0.05 mM forskolin in the presence of 0.5 mM IBMX increased cAMP levels in 
larval body wall muscles by approximately 130% ofthe level observed in forskolin alone 
condition. Thus, IBMX potentiated the effects of forskolin on cAMP levels. 
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forskolin increased cAMP levels by approximately 650 % ( to 191.6 ± 25.8 pmol/mg of 
protein), which is approximately a 2.3 fold increase from the cAMP levels obtained with 
forskolin alone (83.9 ± 9.5 pmol/mg of protein) (Fig 12B, One-Way AN OVA, Tamhane's 
post hoc, p < 0.01). The data suggest that 0.5 mM IBMX is sufficient to act synergistically 
with other cAMP elevating compounds to increase cAMP levels. 
The effect ofthe peptide on cGMP levels was also investigated. One-way ANOVA 
revealed a significant difference in cGMP levels between treatment groups (p<O.Ol). Fig 
13 shows that treatment with IBMX alone resulted in a 260 % increase in cGMP level 
when compared to saline treatment (Tamhane's post hoc, p<0.01), bringing the level of 
cGMP to 3.66 ± 0.31 pmol/mg. Following treatment with 10 nM, 100 nM and 1~M 
DPKQDFMRFamide in the presence of 0.5 mM IBMX, the cGMP levels were 4.04 ± 0.74, 
3.75 ± 0.47 and 3.60 ± 0.33 pmol/mg, respectively (Fig 13). These levels were not 
significantly different from the cGMP level obtained with IBMX alone (Tamhane's post 
hoc, p>0.05). These data suggest that cGMP does not playa role in mediating the 
peptide's effects on muscle tonus. 
3.4.2 Effects of IBMX, forskolin and protein kinase inhibitors on peptide's activity 
To further investigate the possible role of cyclic nucleotide signal transduction 
pathways, the effects of pharmacological agents known to modulate the activity of 
different components of these pathways on physiological actions of the peptide were 
tested. 
IBMX, a broad-spectrum cAMP and cGMP phosphodiesterase inhibitor (Beavo, et 
al., 1970), was used to determine whether slowing the breakdown of cyclic nucleotides 
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would potentiate the effect of a low peptide dose on contraction. Forskolin, an adenylyl 
cyclase activator (ICso =4 11M) was used to determine whether or not elevating cAMP 
level would mimic the physiological response to the peptide. Protein kinase inhibitors 
were used to determine whether blocking cAMP- and cGMP-dependent protein kinases 
inhibits peptide-induced contractions. 
Previously published data showed that DPKQDFMRFamide increases muscle 
tonus of Drosophila larvae in a dose-dependent manner, with a threshold concentration 
of approximately 0.1 11M (Clark et ai, 2008). When DPKQDFMRFamide was applied at 
this threshold level (0.1 11M), the body wall muscles responded with a very small 
increase, 11.6 ± 4.3 IlN, in basal tonus. This response was not significantly increased in 
the presence of 0.5 mM IBMX (Fig 14A, t-test p>O.OS). Treatment with IBMX alone (n=7), 
or forskolin alone resulted in only minimal changes in body wall muscle tonus of 1.1 ± 
7.31lN and 11.6 ± 4.7 IlN, respectively. The primary cellular targets of intracellular 
cAMP and cGMP are the cAMP-dependent protein kinase (PKA) and the cGMP-
dependent protein kinase (PKG), respectively. Hence, I also tested whether or not a PKA 
inhibitor, Rp-cAMPs (ICso =4.9 ± 2.1 11M, Schaap, 1993; Ki =l1IlM, Rothermel and 
Botelho, 1988) and a potent cell permeable PKG inhibitor, Rp-8-pCPT-cGMPS (Ki =O.SIlM, 
Butt et aI., 1994) would antagonize the peptide's effect on muscle tonus. Neither Rp-
cAMPS (100 11M) nor Rp-8-pCPT-cGMPS (10IlM) significantly attenuated the response to 
111M DPKQDFMRFamide (Fig 14B, t-test, p>O.OS). When applied alone, the inhibitors 
did not alter muscle tonus. 
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Fig. 13. DPKQDFMRFamide does not affect cGMP levels in Drosophila body wall muscles. 
The effects of DPKQDFMRFamide on cGMP levels in larval body wall muscles in the 
presence of 0.5 mM IBMX. cGMP levels following 10 min incubation of Drosophila body 
wall muscles in 10 nM, 100 nM and l~M DPKQDFMRFamide in the presence of 0.5 mM 
IBMX did not exceed the cGMP level observed after incubation in 0.5 mM IBMX alone. 
82 
A) 
-Z 
:::1. 
Q) 
tl.O 
c: 
('a 
..c: 
u 
V'> 
:;:l 
c: 
~ 
B) 
45 
40 
~S 
~ 
Z 
:1. 30 
Q) 
tl.O 25 c: 
ro 
..c: 
u 20 
V') 
:::::I 
t: 15 {2 
10 
5 
20 
18 
(7) 
(7) 
16 
14 
12 
10 
8 
6 
4 
2 
0 
O.Olj.tM O.Olj.tM 
DPKQDFMRFamide DPKQDFMRFamide 
+ 
5 X 10"4 M IBMX 
(8) 
:8) 
1\.tM 1 lAM l~M 
OPKQOFMRFamidf;} O~QOFMR.famldQ OPl(QOFMRFamidc 
lOO~M 
Rp-cAMPS 
lOf.lM 
Rp-8-pCPT -cGMPS 
Fig. 14. The application of A) 0.5 mM IBMX, a broad-spectrum phosphodiesterase 
inhibitor and B) 100 11M Rp-cAMPS and 10 11M Rp-8-pCPT-cGMPS, selective cAMP and 
cGMP dependent protein kinase inhibitors, had no effect on the actions of peptide on 
the tonus of Drosophila body wall muscles. 
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4. DISCUSSION 
4.1 DPKQDFMRFamide acts via FR GPCR 
Previous work showed that DPKQDFMRFamide induces larval body wall muscle 
contractions and increases muscle tonus in a dose-dependent manner (Clark et aL, 
2008), but did not identify the cellular targets mediating this effect. To date two major 
classes of FMRFamide receptors have been identified, a FMRFamide-activated Na+ 
channel (FaNaCh) that can be blocked by amiloride (Linguella et aL, 1995), and a 
FMRFamide G-protein coupled receptor (Cazzamali and Grimmelikhuijzen, 2002, 
Meeusen et aL, 2002). Our results suggest that the effect of the Drosophila peptide, 
DPKQDFMRFamide, on the larval body wall muscle contractions are mediated via the 
dFMRFamide G protein coupled receptor. The UAS/GaI4 system (Brand and Perrimon, 
1993) was used to drive the expression of a FMRFamide receptor inverted repeat (FR IR) 
in a tissue-specific manner to silence the receptor gene. When the expression of the FR 
gene (CG2114) was silenced specifically in muscle cells, the excitatory effect of 
DPKQDFMRFamide on muscle tonus was reduced by 85-90 % (Fig lB), and when the 
gene expression was silenced in all tissues, the response was reduced by approximately 
70% (Fig lA). This 15-20 % difference observed between the reduction in response of 
larval muscles with ubiquitous and muscle-specific receptor knock-down might reflect 
different levels of silencing achieved in these fly lines. However, the excitatory effect of 
the peptide on larval muscles was not completely aQolished in either case. If receptor 
expression was completely silenced, and if the peptide acts through the FM RFamide-
GPCR only, then silencing of the FR gene ubiquitously would completely abolish the 
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ability of peptide to increase muscle tonus. However the FR RNAi larvae with the Gal4 
driven in all tissues still responded to 111M DPKQDFMRFamide with an average increase 
in muscle tonus of 9.8 IlN (Fig 9D). At least two possibilities can account for this result. 
First, the larvae used for physiological recordings were heterozygous for the Gal4 and 
UAS-RNAi element. Thus, it is likely that expression of the receptor gene was not 
knocked down completely, and that larval cells retained sufficient expression of the 
dFMRFamide receptor to mediate a weak response to the peptide. An alternative 
possibility is that DPKQDFMRFamide may act via targets other than the FMRFamide 
receptor. Using the ~-arrestin2-green fluorescent protein (~arr2-GFP) translocation 
assay, Johnson et al. (2003) showed that 100 nM DPKQDFMRFamide activates 
myossuppresin receptors expressed in Human Embryonic Kidney (HEK) cells which had 
been simultaneously transfected with a G protein receptor kinase (GRK2) to enhance the 
receptor phosphorylation and arrestin enrolment. Hence, it may be possible that 
DPKQDFMRFamide is acting through more than one receptor to elicit muscle 
contraction. 
4.2 Second messenger pathways 
4.2.1 cAMP and cGMP pathways. The ability of DPKQDFMRFamide to increase 
Drosophila larval muscle tonus is completely abolished by nifedipine and nicardipine 
(Clark et aI., 2008), suggesting that L-type calcium channels are necessary for the 
response to occur. One mechanism underlying the peptide's myotropic effect, 
therefore, may involve peptide upregulation of Ca2+ influx through voltage-gated Ca2+ 
channels. This mechanism is not novel and is utilized, for example, by the myotropic 
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neuropeptide proctolin in the crayfish tonic flexor muscle (Bishop et aL 1991) and by the 
small cardioactive peptides (SCPs) and myomodulins (MMs) in the accessory radula 
closer muscle ofthe marine snail Aplysia cali/ornica (Brezina et aL 1994). cAMP has been 
shown to modulate L-type calcium currents in mammalian (Catterall,2000) , crustacean 
(Bishop et aL, 1991,1987), and insect (Bhattacharya et aL, 1999) muscles, presumably via 
PKA-dependent phosphorylation of L-type Ca2+ channels. On the other hand, cAMP was 
also found to mediate the modulation of muscle contractions by a number of 
neuropeptides (Erxleben et aL, 1995; Bishop et aL, 1991,1987, Trim et aL, 1998) 
including FMRFamide (Willoughby et aL, 1999a), and biogenic amines such as dopamine 
(Knotz & Mercier, 1995) and octopamine (Clark & Lange, 2003). 
cGMP has been shown to modulate calcium channel activity (Taghuchi et aL, 
1997) as well, although by inhibiting Ca2+ channels. Although cGMP has not been 
implicated in the modulatory functions of FMRFamide-like peptides on muscle 
contraction, it has been found to be involved in mediating their effects on synaptic 
transmission (Badhwar et aL, 2006). This suggested that pathways involving cyclic 
nucleotides might playa role in mediating the effects of the peptide on Drosophila larval 
muscle contractions including FMRFamide. 
Several independent lines of evidence presented in this study suggest that cAMP, 
cGMP and their respective protein kinases, PKA and PKG, are not required for the 
peptide to increase muscle tonus in Drosophila larvae. First, the peptide, in the 
presence of a phoshodiesterase inhibitor, IBMX, did not increase cAMP or cGMP levels in 
Drosophila larval muscles. Second, IBMX failed to potentiate the peptide's effect on 
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contraction. Third, inhibitors of cAMP-dependent and cGMP-dependent protein kinases 
failed to reduce peptide-induced contractions. Fourth, neither IBMX nor forskolin 
mimicked the peptide's effect. These observations suggest that changes in cAMP or 
cGMP are neither necessary nor sufficient to mediate the peptide's effect on muscle 
tonus. 
Basal cAMP levels in larval muscle tissue (in the absence of IBMX) were 
approximately 25 pmol/mg of protein. At 50 11M forskolin increased cAMP levels by 
130% from basal levels, and this response was potentiated by the presence of 0.5 mM 
IBMX, a non-selective cAMP/cGMP phosphodiesterase inhibitor. Similar results have 
been reported for locust skeletal and visceral muscles (Lange and Orchard, 1986). Since 
cAMP levels in the presence of both forskolin and IBMX were greater than the levels 
obtained with either forskolin alone or IBMX alone (Fig 4a,b), the IBMX concentration 
appears to be sufficient to reduce cAMP breakdown and generate a synergistic effect 
with forskolin. In contrast to the effects of forskolin, DPKQDFMRFamide in the presence 
of IBMX did not increase cAMP levels above those seen with IBMX alone, suggesting that 
DPKQDFMRFamide does not act by stimulating cAMP production. Also, 
DPKQDFMRFamide in the presence of IBMX did not increase cGMP levels above those 
seen with IBMX alone. This suggests that changes in cAMP and cGMP levels are not 
necessary for the peptide's action on muscle contractions. 
An interesting finding was the difference between the basal cAMP levels in 
Drosophila larval muscle tissue (25 pmol/mg of protein) reported in this study and the 
basal cAMP levels reported in the Drosophila adult tissues and tissues of other insects. 
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The cAMP levels measured in this study appear to be 13-16 fold higher than cAMP levels 
found in the whole adult female CS flies (1.5-1.6 pmol/mg of adult fly, Byers et aL, 1981) 
and in the brain of 3-day-old flies (1.87 ± 0.04, Xu et aL, 1998) using a radioimmunoassay 
technique. Levels of cAMP in the present study are also drastically higher than in 
Diploptera punctata Malpighian tubules (2.39±0.26, pmol cAMP/mg protein, Tobe et aL, 
2005), locust visceral muscle (4.19 ±0.33 pmol cAMP/mg protein, Lange and Orchard., 
1986) and locust skeletal muscle (1.85 ± 0.3 pmol cAMP/mg protein, Evans, 1984). On 
the other hand, the basal levels of cGMP ( "'1 pmol/mg of protein) in larval body wall 
muscles were similar to basal cGMP levels (0.5 , 0.45 and 1.9 pmol/mg, respectively) 
reported in locust skeletal muscles (Evans, 1984), abdomen of the adult giant silkmoth 
A.polyphemus (Schwartz and Truman, 1984) and lobster skeletal muscles (Goy et aL, 
1987). The cause ofthe discrepancy between previously reported basal cAMP levels in 
insect muscles and the levels found here is not clear. However, larval body wall muscles 
used for measuring basal cAMP and cGMP levels in this study were incubated in HL6 
saline, which is rich in amino acids. One could then speculate that the presence of amino 
acids in HL6 saline can act to increase cAMP levels. The fact that basal cGMP levels are 
similar to those reported previously suggests that amino acids do not work to increase 
guanylyl cyclase (GC) activity. An alternative possibility is that the cAMP turnover rate in 
larval muscles is different from those observed in the muscle tissue of adult insects, 
since higher levels of basal cAMP levels (72 pmol/mg of protein) have been previously 
reported in Drosophila larval muscle fibres (Cheung et aL, 1999). 
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To provide additional evidence, I also tested the effects of pharmacological 
agents that activate or inhibit components of cAMP and cGMP pathway on the ability of 
the peptide to increase muscle tonus. The peptide-induced contracture was not 
potentiated by IBMX, a non-selective cAMP/cGMP phosphodiesterase inhibitor, nor was 
the response to the peptide mimicked by IBMX or forskolin. Since the concentration of 
forskolin increased cAMP levels in the tissue, changes in cAMPdo not appear to be 
sufficient to elicit contracture. 
The PKA inhibitor, Rp-cAMPS and the PKG inhibitor, Rp-8-pCPT-cGMPS, were also 
used to examine the possible role of cAMP and cGMP pathways in the peptide-induced 
contractions. The concentrations of Rp-cAMPs (100 ~M) and Rp-8-pCPT-cGMPS (10 ~M) 
used in this study were shown to successfully reduce the ability of DF2, a crayfish 
FMRFamide-like peptide, to enchance EJP amplitude by 76 % and 40 % ,respectively 
(Badhwar et aL, 2006). In the present work, neither kinase inhibitor altered the ability of 
DPKQDFMRFamide to induce an increase in muscle tonus. 
4.2.2 PLC-IP3 pathway. IP3 has been implicated in mediating the excitatory 
effects of several neuropeptides, including FMRFamide (Willoughby et aL, 1999b, 
Falconer et aL, 1993) and proctolin (Hinton & Osborne, 1995, Baines et aL,1990), on 
muscle contractions. 
Since DPKQDFMRFamide increases muscle tonus with a relatively slow time rise 
course and induces irregular phasic muscle contractions (Clark et aL, 2008), the 
regulation of intracellular Ca2+ may be of importance for the peptide's effects. One of 
the main signalling molecules regulating Ca2+ oscillations in the cell is IP3 which 
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stimulates the release of Ca2+ from the intracellular stores via IP3 receptors (Berridge, 
1984, 2009). 
To test this hypothesis, muscle tonus was recorded in several mutants with 
disturbances in functionality of molecular components of the PLC-IP3 pathway. Although 
several PLC types are present in the celt only PLC-~ is activated by a G protein coupled 
receptor (Vauquelin & von Mentzer, 2007; Krauss, 2001). In Drosophila melanogaster 
two genes encode for PLC-~; norpA and plc-21c. norpA mutants exhibit 97-99 % 
reduction in PLC activity compared to control flies, as determined by in vitro PLC assays 
of eye and whole head homogenates (Inoue et aI., 1988, Pearn et aI., 1996). 
Unfortunately, the level of PLC activity in tissues of Plc-21C mutants remains unknown. I 
tested the effects of 1 ~M DPKQDFMRfamide on muscle tonus of several norpA mutants, 
w* norpA33, w*norpA36 and norpA7, and one PLC-21C mutant. Peptide-induced 
contractions in these mutants were neither reduced nor augmented when compared to 
control larvae suggesting that PLC-IP3 pathway is not involved in mediating the peptide's 
effect on muscle contacture. 
One could argue that the estimated PLC activities from the adult head tissues of 
norpA mutants do not necessarily represent the activity of the PLC in the rest of the 
norpA adult tissues or larval tissue, especially since PLC-~ is encoded by two different 
genes. This, together with the fact that the PLC activity of PLC-21C mutants is unknown, 
brings into question the interpretation of the present data. However, two lines of 
evidence suggest that PLC activity in norpA mutants is not confined to the CNS. The first 
stems from the molecular and genetic studies of PLC-~ encoding genes. Although early 
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molecular characterization and physiological studies indicated that norpA expression is 
confined to the retina {Bloomquist et aI., 1988}, later immunodetection of norpA protein 
via Western blots showed the presence of a 130 kDa protein in the leg, thorax and 
abdomen of adult flies {Zhu et al.,1993}, suggesting that PLC-~ also plays an important 
role in transduction pathways outside the CNS. Similarly, hybridization of plc-21 cDNA 
probes to RNA blots revealed that this gene encodes two transcripts, 6.6 kb and 7 kb 
long, the smaller of which was detected throughout larval development and in adult 
heads and bodies {Shortridge et aI., 1991}. The second line of evidence that norpA gene 
function is disturbed in tissues other than eye and CNS comes from the physiological 
studies on norpA mutants. To date, Drosophila norpA (no receptor potential) mutants 
have not only been successfully used to elucidate the function of PLC in 
phototransduction {Pak and Shortridge, 1991}, but also in modulation of epithelial fluid 
transport {Pollock et al.,2003} and larval muscle L-type Ca2+ channels currents {Gu and 
Singh., 1998}. For example, fluid transport assays performed on Malpighian tubules 
showed approximately 60% reduction in neuropeptide-stimulated secretion rate in 
norpA36 mutants compared to wild type flies (Pollock et al.,2003), suggesting that norpA 
function is not confined to the phototransduction pathway of adult flies. The L-type Ca2+ 
current is reduced in muscle tissue of norpA36 larvae by 20 %, hence comprising 80% of 
the wild type Ca2+ current {Gu and Singh., 1997}, suggesting that norpA also plays an 
important role in intracellular signalling in larval muscle tissue. 
When PLC is activated, it stimulates the production of IP3, which then binds to IP3 
receptors present on internal Ca2+ stores and releases Ca2+ into the cytosol. The results 
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obtained with norpA mutants, suggest that IP3 is not involved in mediating peptide-
induced contractions. This result is corroborated by the ability of peptide to also induce 
contracture in IP3 receptor mutants. Only one gene in Drosophila, itpr-83, encodes for an 
IP3 receptor (IP3R) (Hasan and Rosbash, 1992). 
A reverse-transcription-based competitive polymerase chain reaction assay (RT-
QPCR) detected itpr-83 gene expression in heads, eyes, antennae and legs of adult flies, 
from which the expression was most strongly pronounced in antennae, suggesting that 
the IP3 receptor may have a role in olfaction (Hasan and Roosbash, 1992). Confocal 
microscopy, utilized to trace the expression of fluorescent compounds specific for RyR 
(TX-R-BODIPY-ryanodine), IP3R (FL-Heparin), and thapsigargin-sensitive SERCA (FL-
BODIPY-thapsigargin), demonstrated abundant localization of IP3 receptor protein in the 
cells of epidermal, muscle and digestive tract tissue in late embryonic stage and adult · 
flies (Vazquez-Martinez ., 2003). The expression studies suggest that IP3 plays an 
important role in variety of tissues. Larvae of this particular mutant were shown to 
express 50% reduction in itpr-83 mRNA levels when compared to wild type larve (Klose 
et aL 2010). Although the stimulatory effects of DPKQDFMRFamide on peak Ca2+ levels 
in presynaptic terminals (Klose et aL, 2010) and on EJP amplitude (Klose et aL, 2010; 
Dunn, 2003) are abolished in IP3 receptor mutants, the ability of the peptide to increase 
muscle tonus was not affected in the present work. This suggests that IP3 is not 
necessary for the peptide to induce contracture postsynaptically. 
4.2.3 CaMKII. Previously published evidence suggests that influx of Ca2+ through 
L-type calcium channels is necessary for DPKQDFMRFamide to increase muscle 
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contractions (Clark et aL,2008). This interpretation is based on the observation that 
peptide-induced contractions are drastically reduced in Ca2+free saline or by L-type 
channel blockers. Currently it is not known if DPKQDFMRFamide causes membrane 
depolarization that could increase the opening of the voltage-gated Ca2+ channels. Some 
influx of Ca2+ presumably leads to an increase in intracellular Ca2+ levels; however, it is 
not clear which effectors act downstream of Ca2+ influx to enhance contracture. 
CaMKIl appears as a likely effector that could mediate the effect of the peptide 
on muscle contracture from at least two standpoints. First, a previous study reported 
CaMKIl necessary for DPKQDFMRFamide, the same peptide tested in this study, to 
increase the amplitude of EJPs, and hence necessary for the neuropeptide's stimulatory 
effects on synaptic transmission to occur (Dunn and Mercier, 2005). Secondly, CaMKIl 
has been implicated in regulating several muscle proteins involved in regulation of 
calcium levels (Jahn et aLI 1988, Dzhura et aLI 2000) and muscle contractility (Phietzer, 
2001, Sutherland and Walsh, 1989). For example, treatment with CaMKIl inhibitors 
abolishes Ca2+ induced enhancement of L-type calcium currents in isolated toad smooth 
muscle cells (McCarron et aI., 1992) and rabbit ventricular myocytes (Anderson et aLI 
1994) most likely by the direct phosphorylation of the 55-kDa and the 165-kDa protein 
of voltage gated (L-type) calcium channels (Jahn et aI., 1988; Dzhura, 2003). In addition, 
CaMKIl is able to regulate the release and reuptake of Ca2+ from internal stores by 
modulating the activity of RYR channels and by increasing the activity of SERCA, a Ca2+ 
ATPase pump that is involved in sequestering Ca2+ from the cytoplasm (for review see 
Grueter et aI., 2007) . In the smooth muscles, the regulatory light chain of myosin is 
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phosphorylated by Ca2+ /calmodulin-dependent myosin light chain kinase (MLCK), which 
leads to the activation of myosin ATPase and muscle contraction. Inhibition of CaMKIl by 
KN62 abolished the phosphorylation of MLCK in isolated bovine tracheal smooth muscle 
cells, which was associated with a decrease in the Ca2+ sensitivity of regulatory MLCK 
phosphorylation. This mechanism was proposed to lead to desensitization of smooth 
muscle to subsequent contractile stimuli (Pfitzer, 2001). Contrarily, phosphorylation of 
smooth muscle protein caldesmon by CAMKII prevents its binding to myosin, which may 
lead to an increase in cross bridge cycling and generation of contractile force 
(Sutherland & Walsh, 1989). 
This study reports that ala11arvae, exhibiting 30-40% reduction in CaMKIl activity 
(Griffith et ai, 1993), respond to DPKQDFMRFmamide with a tonus change comparable 
to the control, UAS-ala larvae, exhibiting normal levels of CamKIl activity. Even after ala1 
larvae had been submitted to a heat-shock to reduce the CaMKIl activity even further 
(by approximately 70-100%), the response to the peptide was similar to the heat 
shocked UAS-alallarvae. This suggests that modulation of muscle contractions by the 
peptide does not require CAMKII. 
Contrary to what would be predicted, the response to DPKQDFMRFamide was 
actually potentiated in heat-shocked ala1 and UAS-ala larvae by approximately 150 and 
100 %, respectively. Drummond et al. (1986) reported that heating single fura-2 loaded 
Drosophila larval salivary gland cells to 35°C resulted in a 10-fold increase in intracellular 
Ca 2+ concentration even in the Ca2+-free saline, suggesting that a large portion ofthe 
increase comes from releasing Ca2+ from internal stores. The recovery of [Ca2+]i was 
94 
relatively slow, starting approximately 45 min after the bath temperature had cooled to 
25°C (Drummond et aL, 1986). Assuming that heat shock affects Ca2+ concentration in 
the muscle cells in a similar way, an increase in intracellular Ca2+ after the heat shock 
treatment could account for the augmentation of the response to the peptide observed 
following the heat shock treatment. 
Although the alai transgenic fly line has been used successfully to deduce 
CaMKII functions in previous electrophysiological (Griffith et aL, 1994, Dunn and 
Mercier, 2005) and behavioural assays (Griffith et aL, 1993, Joiner and Griffith, 1997, 
Broughton et aL, 2003), some limitations may apply when it is used in muscle 
contraction assays. At room temperature, alai flies have very low expression of CaMKII 
inhibitory peptide, and hence it is possible that the residual CaMKII concentration is 
sufficient to respond to peptide-dependent Ca2+ influx and modulate its effectors 
(Griffith et aL, 1993). Heat shock is reported to significantly increase levels of CaMKII 
inhibitory peptide (Griffith et aL, 1993), but at the same time it also increases the 
intracellular Ca2+ levels (Drummond et aL, 1986). Thus, a subtle dependence on CaMKII 
may be masked by the effects that overabundance of intracellular Ca2+ exerts on muscle 
contractions. 
To confirm the findings from alai flies, I also tested the effects of a 
pharmacological CaMKII inhibitor, KN-93, on the DPKQDFMRFamide-induced muscle 
contractions. The application of KN-93, at the same concentration and incubation time 
at which it abolished the peptide's ability to enhance EJP amplitude (Dunn and Mercier, 
2005), did not block the peptide's ability to increase muscle contractions. 
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4.3 Presynaptic vs postsynaptic effects 
Two lines of evidence from this study support the idea that the increase in tonus 
of Drosophila larval body wall muscles is mediated by direct actions of 
DPKQDFMRFamide on the muscle fibres and not by increasing spontaneous release of 
neurotransmitters from nerve terminals. 
The first comes from experiments in which flies were manipulated genetically in 
a manner that should reduce dFMRFamide receptor gene expression. The response to 1 
j..lM DPKQDFMRFamide was severely attenuated in larvae designed to reduce 
dFMRFamide receptor expression specifically in muscle tissue (24B-GaI4/+; UAS-FR 
RNAi/+), but not in larvae designed to reduce dFMRFamide receptor expression 
specifically in neurons (elav-GaI4/+; UAS-FR RNAi/+). This suggests that the expression 
of the dFM RFamide receptor on the postsynaptic cell is necessary for this response to 
the peptide to occur, and that the expression of this same receptor on presynaptic nerve 
terminals is not sufficient to allow the peptide to increase muscle tonus. 
The second line of evidence comes from experiments investigating second 
messenger systems that mediate the peptide's actions. The increase in muscle tonus 
does not appear to require CaMKIl activity or the IP3 receptor. Previous work, however, 
has shown that DPKQDFMRFamide acts presynaptically via the IP3 receptors and CaMKIl 
to increase the amplitude of EJPs (Dunn, 2004; Dunn and Mercier, 2005). This effect on 
EJP amplitude is completely abolished in heat shocked alallarve which express CaMKIl 
inhibitory peptide and by KN-93, a pharmacologicalCAMKIl inhibitor (Dunn & 
Mercier,200S). In addition, the peptide's ability to increase EJP amplitude was 
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completely abolished in two IP3 receptor mutants (Dunn, 2004; Klose et aL,2010). Taken 
together these studies indicate that DPKQDFMRFamide-dependent enhancement of 
neurotransmitter release from presynaptic terminals requires activation of IP3 receptors, 
presumably to release Ca2+ from internal stores. This is confirmed by the evidence that 
DPKQDFMRFamide increases peak Ca2+ currents in 1b boutons (Klose et aL, 2010). 
Downstream from the Ca2+ increase, DPKQDFMRFamide-induced modulation of 
neurotransmitter release requires CaMKl1. If the peptide-induced increase in 
neurotransmitter release was responsible for peptide's myogenic effects, one would 
predict that inhibition of the pathways involved in effects on the EJP amplitude and peak 
Ca2+ increase (IP3 receptors and CaMKII) would also inhibit the ability of the peptide to 
increase muscle tonus. The present data indicate that this was not the case. By applying 
the same genetic and pharmacological approaches as those used by Dunn and Mercier 
(2005) and Klose et aL (2010), this study showed that inhibition of CaMKIl and IP3 
receptors does not abolish the peptide's stimulatory effects on muscle tonus. In 
conclusion the mechanisms required for DPKQDFMRFamide's postsynaptic effects to 
occur are not the same as those required for presynaptic effects. This further supports 
the idea that peptide's stimulatory effect on muscle tonus in the absence of nerve 
stimulation is postsynaptic. 
4.4 Conclusions and perspectives 
This study provides compelling evidence that DPKQDFMRFamide acts 
postsynaptically via the FMRFamide G-protein coupled receptor (FR) to increase muscle 
tonus. However, the results also show that the response to DPKQDFMRFamide is not 
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completely abolished by ubiquitous silencing of the FR. This finding, together with the 
evidence provided from pharmacological characterization of the dFMRFamide receptor 
cloned and expressed in HEK and CHO cells (Johnson et aL, 2003, Cazzamali and 
Grimmelikhuijzen, 2002), suggests that OPKQOFMRFamide might also act on receptors 
other than FR such as the Drosophila myosuppressin receptors. This seems unlikely 
because the physiological effects of OMS on heart and gut contractions are inhibitory, 
opposite to the effects of FMRFamide-containing peptides. Hence it seems unlikely that 
binding of OPKQOFMRFamide to OMS receptors on muscle cells would produce 
stimulatory effects. Further investigations are needed to reveal the relevance of the 
myosuppressin receptor and possible involvement of other receptors in mediating the 
physiological actions of OPKQOFMRFamide and other FMRFamide-containing peptides. 
The present data indicate that cAMP, cGMP, IP3 and CaMKIl are not likely to be 
involved in mediating the peptide's stimulatory effect on muscle tonus. Previously it 
was shown that FMRFamide can reduce neurotransmitter release from Aplysia neurons 
via arachidonic acid (AA) (Piomelli et aL, 1987, Taussig et aL, 1989), a product of 
membrane phosholipid hydrolysis initiated by phospholipase A2 (PLA2). The possible 
involvement of AA signalling pathway in mediating effects of Drosophila FMRFamides 
remains to be examined. This opens the possibility that either AA or some unknown 
messenger is activated by the OPKQOFMRFRamide (Fig 15A). 
The myotropic effect of OPKQOFMRFamide on larval body wall muscles does not 
appear to require IP3 -dependent release of calcium from the internal stores, since 
larvae with disrupted PLC and IP3 receptor function are able to respond to the peptide. 
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Wegener & Nassel (2000) showed that proctolin-induced contractions in the 
hyperneural muscle of the cockroach Periplaneta Americana depend greatly on the 
release of calcium from the sarcoplasmic reticulum via ryanodine receptors, but not on 
the IPTinduced Ca2+ release. Hence, the possibility that the peptide increases 
intracellular calcium at least in part via calcium-induced calcium release through 
ryanodine channels has not been excluded. 
The myotropic effect of DPKQDFMRFamide requires influx of calcium via voltage 
gated calcium channels (VGCC) (Clark et aL, 2008), but the mechanisms that lead to the 
activation ofthese VGCC remain unknown. In Drosophila muscle tissue, both cAMP and 
PLC-DAG signalling molecules have been shown to modulate L-type calcium channel 
currents (Bhattacharya et aL 1999, Gu an Singh, 1997). Our results suggest that neither 
of these pathways is involved in the peptide-induced modulation of muscle contractions. 
The other possibility is that the peptide-activated G-protein coupled receptor is directly 
modulating the activity of calcium channels (Fig 15B). Studies have shown that G protein 
a and ~y subunits can bind directly to ion channels, modulate their activity (Dascal et aL, 
2001, Jiang and Bajpayee, 2009) and, hence, modulate cell excitability. Further 
investigation is necessary to elucidate the molecular mechanisms linked to the 
dFMRFamide receptor. 
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A) 
DPKQDFMRFamide 
1 
t Muscle contraction 
B) 
()fJKU()~MKl-amlde 
-------------------~ 
1 
t Muscle contraction 
Fig. 15. Hypothetical mechanisms mediating neuropeptide modulation of Drosophila 
larval body wall muscles. 
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